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ABSTRACT OF DISSERTATION

NITRATION AND INACTIVATION OF MANGANESE SUPEROXIDE DISMUTASE
PLAYS A CRITICAL ROLE IN METABOLIC SWITCH
Alzheimer’s disease (AD) is a multifactorial, progressive, age-related
neurodegenerative disease. Oxidative stress hypothesis is most prevalent and is gaining
significant support. Inspite of the progress achieved on oxidative stress related damages
in AD brain; the modification occurring on the various cellular antioxidant enzymes
antioxidant has not been identified. Tyrosine nitration, a marker for peroxynitrite
induced oxidative damage to protein is widespread in AD brain and Manganese
superoxide dismutase (MnSOD), primary mitochondrial antioxidant enzyme is prone to
peroxynitrite induced nitration and inactivation. Nitration of proteins involved in energy
metabolism has been demonstrated in AD brain, which may explain the altered glucose
metabolic status existing in AD brain. In the present study, we investigated the effect of
tyrosine nitration of MnSOD on energy metabolism by the use of AD mouse model and
cultured neuronal cells. The AD mouse model was generated from a double homozygous
knock-in mouse, designated as APP/PS-1 mice, by incorporating the Swedish familial
AD mutations in APP and P264L familial AD mutation in PS – 1. These animals
develop age dependent increase in Aβ deposition beginning at 6 months along with an
increase in insoluble Aβ1-40/Aβ1-42 levels. Genotype and age associated increase in
nitration of MnSOD without any change in protein levels was also observed. MnSOD
activity and mitochondrial respiration was decreased in APP/PS-1 mice. There was also
concomitant increase in levels of lactate, an index of glycolytic activity in APP/PS-1
mice. To directly investigate the role of MnSOD inactivation in mitochondrial function
and subsequent alteration in glycolytic activity, SH-SY5Y neuroblastoma cells line was
used and treated with peroxynitrite. Enhanced nitration and reduction in the activity of
MnSOD was observed upon peroxynitrite treatment. Peroxynitrite treatment also
induced mitochondrial dysfunction, but MnSOD was inactivated at a concentration of
peroxynitrite 10 times lower than that required to inhibit mitochondrial respiration.
Mitochondrial dysfunction was alleviated by SOD mimetic and reproduced by MnSOD
siRNA. The decline in mitochondrial function did not result in decreased ATP levels but
was accompanied by an up-regulated glycolysis signified by high levels of lactate and
lactate dehydrogenase activity but decreased activity of pyruvate dehydrogenase. These

changes were prevented by SOD mimetic and were promoted by MnSOD siRNA.
Specific reduction of MnSOD in MnSOD heterozygous knock-out mice resulted in
decreased RCR and complex I activity with increased lactate levels. Taken together,
these data demonstrate a critical role of MnSOD in influencing the mitochondrial
function and thereby the switch in the energy metabolism switch that might occur under
the pathological condition of MnSOD deficiency.
KEYWORDS: Alzheimer’s disease, Mitochondria, MnSOD, Nitration, Energy
Metabolism
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CHAPTER ONE
NEURODEGENERATIVE DISEASE, ALZHEIMER’S DISEASE, MANGANESE
SUPEROXIDE DISMUTASE AND PEROXYNITRITE
INTRODUCTION
The mammalian brain occupies a relatively small percentage of body weight (2%)
but consumes an inordinate fraction (20%) of total body oxygen consumption. Oxygen
supply is essential for the maintenance of cellular respiration and the production of
energy in the brain. ATP produced in the mitochondria, by complete oxidation of
glucose to carbon-dioxide and water in the presence of oxygen, is the obligate energy
source of the brain. In the process of production of energy in mitochondria, incomplete
reduction of oxygen can form superoxide radicals and subsequent reactive oxygen
species (ROS) capable of damaging macromolecules. Brain is particularly sensitive to
ROS owing to its high level of oxygen consumption and inadequate anti-oxidant defenses
(Floyd and Carney, 1992). Oxidative stress hypothesis has been proposed and is gaining
momentum towards unraveling the pathogenesis of neurodegenerative diseases including
Alzheimer’s disease (AD) (Markesbery, 1997). Oxidative stress is evidenced by protein
oxidation, lipid peroxidaton (Butterfield and Lauderback, 2002), 3-nitrotyrosine (3-NT)
levels (Castegna et al., 2003; Smith et al., 1997), advanced glycation end products and
DNA/RNA oxidation products (Mecocci et al., 1994).

Peroxynitrite is a consistent

mediator of 3-NT formation (Smith et al., 1997; Yamakura et al., 1998). Manganese
superoxide dismutase (MnSOD), the primary anti-oxidant enzyme in the mitochondria is
highly sensitive to peroxynitrite induced nitration of its tyrosine residues and thereby
becomes inactivated (MacMillan-Crow et al., 1996; Yamakura et al., 1998). Because
mitochondria are the major source of superoxide production under physiological
conditions, the function of MnSOD in catalyzing the dismutation of superoxide to
hydrogen and molecular oxygen is vital in preventing any accumulation of superoxide
and thereby oxidative stress. Studies from our lab have demonstrated that MnSOD
protects mitochondrial function (Yen et al., 1999).
1

Thus, inactivation of MnSOD

presumably would lead to a compromised mitochondrial function and thereby reduction
in cellular energy production from oxidative phosphorylation. Interestingly, in tumors
and transformed cells, glycolysis is known to compensate for the loss of mitochondrial
function in producing energy for cellular processes (Gatenby and Gillies, 2004).
However, whether similar compensation will occur in non-tumor brain tissue is unclear.
The following review will focus on the existence of oxidative stress in Alzheimer’s
disease, its consequence on MnSOD activity, mitochondrial function and glycolysis and a
possible role for MnSOD in these alterations.
NEURODEGENERATION AND NEURODEGENERATIVE DISEASES (NDD)
It is estimated that almost 400 million individuals suffer from neurological
diseases in the world (Welsh, 2006b). The word “Neurodegeneration”, is etymologically
comprised of ‘neuro’, designating nerve cells, and ‘degeneration’, referring to a process
of losing structure or function. Thus, it refers to any pathological condition primarily
affecting neurons (Przedborski et al., 2003).

NDD are a heterogeneous group of

disorders characterized by gradual progression, selectively affecting specific subsets of
neuronal populations in specific functional anatomic systems (Lin and Beal, 2006). The
inciting or the causative factors of NDD are not clearly understood, but NDD are known
to progress relentlessly and are always related to neurons.

So, neoplasm, edema,

hemorrhage and trauma of the nervous system are not neurodegenerative diseases and
neither is multiple sclerosis, which does not affect neurons but affects the myelin sheath.
There are hundreds of known NDD and many of these overlap with each other
clinically and pathologically rendering the classification challenging (Burn and Jaros,
2001). To avoid confusion, the classification is based on predominant clinical feature or
topography of the predominant lesion. Accordingly, NDD of the CNS is grouped into
those of the cerebral cortex, the basal ganglia, the brain stem and cerebellum. But each
group is represented by more than one disease, so within each group, a given disease is
further classified based on its main clinical features. For example, the cerebral cortex
group includes dementing and non-dementing disorders, Alzheimer’s disease being the
predominant dementing disorder. Diseases affecting the basal ganglia are characterized
2

by abnormal movements classified as hypokinetic or hyperkinetic. Parkinson disease is
hypokinetic disease while Huntington disease is an example of a hyperkinetic disorder.
Cerebellar diseases comprise three main neuropathological types: cerebellar cortical
atrophy, pontocerebellar atrophy and Friedreich ataxia.

Spinal cord NDD includes

Amyotrophic lateral sclerosis and spinal muscular atrophy (Przedborski et al., 2003).
With the dawn of molecular biology and advent of state-of-the-art techniques in the past
two decades, the classification of NDD, presently is based on molecular characteristics.
Neuropathological entities that formerly belonged to very different categories are now
grouped together because of common molecular defects have been identified. This
classification has given rise to the groups of trinucleotide-repeat diseases (Cummings and
Zoghbi, 2000), prion diseases (Prusiner, 1998), synucleinopathies (Galvin et al., 2001)
and tauopathies (Goedert and Spillantini, 2001).
Though a great many NDD have been identified, no clear cut picture about the
causes has emerged. A risk factor that is consistently linked to the development of NDD
is ageing.

The probability of developing a neurodegenerative disorder dramatically

increases in the sixth, seventh and eighth decades of life. There is a high probability that
a person who lives to the age of 85 years will suffer from Alzheimer’s disease (AD).
Parkinson’s disease (PD) is most common in those above the age of 70 years and the
probability of developing amyotrophic lateral sclerosis (ALS) rises sharply above the age
of 40 years (Mattson and Magnus, 2006). The relative contribution of genetic and
environmental factors to the etiology of NDD has been a subject of intense research. The
genetic basis was suggested based on findings of familial occurrence of NDD. The
genetic causation can be autosomal dominant trait (Huntington disease), autosomal
recessive trait (familial spastic paraparesis), an X-linked trait (spinal and bulbar muscular
atrophy) or a maternally inherited trait. Sporadic experienced are also being thoroughly
studied. Oxidative stress has emerged as an important factor in mediating the effect of
many environmental and pathological conditions.

3

ALZHEIMER’S DISEASE AND ITS PREVALENCE
Despite enjoying the longevity nowadays, people have to be aware of the fact that
the chances of suffering from dementia would be higher in their senior years. Dementia
may be caused by more than 60 different diseases, and affects a significant proportion of
the elderly population (Welsh, 2006b). Alzheimer’s disease (AD), the most common of
the dementias, is estimated to account for approximately 60 percent of all dementia
(Small et al., 1997). Alzheimer’s disease, named for Alois Alzheimer, who first described
in 1907, the findings of senile plaques and neurofibrillary tangles in the hippocampus and
neocortex of a middle aged woman with memory deficits and progressive loss of
cognitive function. Estimates of numbers affected worldwide are greater than 18 million
(http://www.alzheimer’s.org), with over 5 million people living in the USA. The
epidemic of AD is expected to quadruple by the year 2047. The greatest risk factor for
AD is aging with the prevalence of this disease doubling every 5 years after age 65 and
approaches 50% by age 85. Although AD is not caused by aging, nor is it an inevitable
part of the aging process, it is age-related (Welsh, 2006b). With the proportion of elderly
people in the population increasing steadily, and an expected three quarters of the world
population

over

60

years

of

age

by

2025

(http://www.who.int/ageing/ActiveAgingPolicyFrame.pdf), the financial, societal and
emotional costs of AD will be staggering.
AD is a complex age-related neurodegenerative disorder, with retrograde
progressive amnesia that is mentally and physically completely debilitating (Dawbarn
and Allen, 2007). AD is a slow disease, starting with mild memory loss and ending with
severe dementia. As the neuronal cells die slowly, the individual’s ability to function
worsens progressively leading eventually to a loss of most functional skills, including the
ability to read, reason, communicate and understand spatial relationships. The course the
disease takes and speed of progression vary from person to person. On an average, AD
patients live from 8 to 10 years after they are diagnosed, though the disease can last for as
many as 20 years. Brain regions involved in learning and memory processes, including
the temporal and frontal lobes, are reduced in size in AD patients as the result of
degeneration of synapses and death of neurons. Because there can be other causes of
4

memory loss, definitive diagnosis of AD requires postmortem examination of the brain,
which must contain sufficient numbers of "plaques" and "tangles" to qualify as affected
by AD (Mattson, 2004). These are the classical hallmark pathologies of Alzheimer’s
disease as observed by Alois Alzheimer (1864 – 1915) and subsequent researchers
(Dickson, 2001). Apart from this, selective neuronal loss and shrinkage, atrophy of the
brain, synapse loss, neuropil thread formation and amyloid angiopathy are also
manifested in AD brain.

A definitive diagnosis cannot be made without

neuropathological confirmation. The core of neuritic plaques is composed of β-amyloid
(Aβ) that has aggregated into densely packed, insoluble, β-pleated sheets (Peskind, 1996),
with dystrophic neurites, abnormal synapses, activated microglia and fibrous astrocytes
located on the periphery. Neurofibrillary tangles (NFT) mainly consist of paired helical
filaments that are predominantly composed of abnormally phosphorylated tau protein
(Peskind, 1996).
Aβ is normally dissolved in the extracellular fluid of the brain and cerebrospinal
fluid. But under certain circumstances, it forms into small fibrils which adopt a β-sheet
formation, that precipitate out of solution as fibrillar aggregates and are deposited
extracellularly as plaques. Aβ plaques vary in size from about 5 to 200 μm across and
can be divided as diffuse or neurotic plaques based on their structural appearance.
Diffuse plaques consist of homogeneous deposits of fibrillary material without any local
reactive glial cells or abnormal neuritic processes.

Neuritic plaques have a more

heterogeneous sculpted appearance with a central dense core, with peripheral halo. The
main component of diffuse plaques is Aβ42 whereas Aβ40 predominates in neuritic
plaques. The halo contains additional elements in the form of glial and abnormal swollen
neuritic processes. The glial component consists mainly of astrocytic processes and of
microglial cells. The formation of Aβ plaques is not entirely specific for AD but also
occur in normal aging, Down’s syndrome and some other neurodegenerative diseases.
The essential difference between AD and normal aging with respect to plaques is that
they are more numerous in AD. Although neuritic plaques are composed predominantly
of Aβ, many other molecules are also seem to be concentrated in them. Some of the
proteins include enzymes acetylcholinesterase (Mesulam and Asuncion Moran, 1987) and
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α1 – antichymotrypsin (Abraham et al., 1988), complement components (Eikelenboom
and Stam, 1982), apolipoproteins and growth factors and their receptors.
NEURITIC PLAQUES
The amino acid sequence of Aβ, the predominant content of neuritic plaque, was
first obtained from cerebrovascular amyloid (Glenner and Wong, 1984). The plaque core
of amyloid protein from the cerebral cortex of AD brain was also purified and
characterized and found to be similar to that of amyloid of cerebrovascular origin found
in the brains of Down’s syndrome patients. In all cases Aβ was found to consist of 40 –
42 amino acid sequence. In 1987, Aβ peptide was shown to be derived from a larger
precursor, amyloid precursor protein (APP) (Figure 1.1) (Goldgaber et al., 1987) and the
gene was later localized to the long arm of chromosome 21. APP is synthesized in the
endoplasmic reticulum (ER) and glycosylated within the ER and Golgi apparatus. This is
a type I transmembrane glycoprotein with a relatively long N-terminal extracellular
domain and a short C-terminal cytoplasmic domain. Of the 18 exons which encode for
APP, exons 7, 8 and 15, encoding the extracellular domain, are subject to alternative
splicing. There are seven known splice variants of the protein; major isoforms being 695,
751 and 770 amino acids (aa) in length. APP is expressed in all tissues, but the exclusive
isoform expressed in neurons of the central and peripheral nervous system is APP695
(Dawbarn and Allen, 2007), whereas 751 aa and 770 aa transcripts are expressed both in
neural and non-neural cells (Selkoe, 1996). A battery of functions has been attributed to
APP including neurite outgrowth, cell adhesion molecule, synaptogenesis and cell
survival (Magara et al., 1999; Perez et al., 1997).
Aβ domain is present between the amino acids 672 and 712/714 of APP which
can undergo concerted endoproteolytic cleavage by several proteases namely α, β and γ
secretase in either a non-amyloidogenic pathway (NAP) or amyloidogenic pathway (AP)
depending on the sequence of action of secretases. In NAP, the APP is first cleaved by
α-secretase, whose activity is ascribed to the members of ADAM (a disintegrin and
metalloprotease) family of proteases (ADAM 17, ADAM 10 and ADAM 9) (Dawbarn
and Allen, 2007), resulting in secretion of an N – terminal ectodomain fragment called
6
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Figure 1.1 Processing of Amyloid precursor protein (APP)
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sAPPα, and the retention of an 83 aa C – terminal fragment called C83 tethered to the
membrane. α-secretase cleaves APP at amino acids 687/688, thereby precluding the
formation of Aβ. sAPPα may be involved in the enhancement of synaptogenesis, neurite
outgrowth and neuronal survival, and is considered to be neuroprotective.
In AP the APP is cleaved by β-secretase between 671/672 aa producing a N
terminal fragment called sAPPβ and a C terminal fragment of C99 attached to the
membrane. A sequential cleavage of C99 by γ-secretase leads to the formation of Aβ of
length 40 or 42 aa (Aβ40 or Aβ42). Under normal conditions very small amounts of
Aβ1-40 and Aβ1-42 are formed in the cell; in both CSF and cell culture Aβ1-40 is the
major component (50% - 70%), with Aβ1-42 as the minor component (5% - 20%)
(Murphy et al., 1999). Neuronal and non-neuronal cells process APP differently. The αsecretase pathway predominates in non-neuronal cells and so little of Aβ is produced.
NEUROFIBRILLARY TANGLES (NFT) AND AD
The primary component of NFTs is the Tau protein.

Tau is a microtubule

associated protein (MAP) that maintains the microtubule network in neurons for axonal
transport. Tau is expressed throughout the central nervous system, but predominantly in
neuronal axons. MAP1A/MAP1B, and MAP2 are the other proteins required to promote
assembly and stabilization of microtubules. Tau is the smallest, with a biological activity
depending on phosphorylation of normally present 2-3 mole of phosphate/mole of protein
for optimal activity (Kopke et al., 1993). To date, the most established and the most
compelling cause of dysfunctional tau in AD is the abnormal hyperphosphorylation of tau
leading to accumulation of tau as intraneuronal tangles of paired helical filaments
(PHFs), twisted ribbons and/or straight filaments (SF) (Iqbal et al., 2000).

The

hyperphosphorylation of tau can be due to a conformational change (Jicha et al., 1997) in
diseased brain, making it a better substrate for phosphorylation and/or a worse substrate
for dephosphorylation. The most important factor for the hyperphosphorylation of tau is
the imbalance between tau kinases and/or phosphatases in the favor of the former (Pei et
al., 2003). Abnormally hyperphosphorylated tau isolated from AD brain polymerizes into
PHF/SF tangles in vitro at pH 6.9 under reducing conditions (Alonso et al., 2001),
8

consistent with findings in AD brain. The hyperphosphorylated tau sequesters normal tau
and other MAPs causing inhibition and disassembly of microtubules and microtubular
network leading to neurodegeneration.
CLASSIFICATION OF ALZHEIMER’S DISEASE
Classification of AD is based on the age of onset and hereditary characteristics.
Two main types have been identified, Familial AD (FAD) and Late-Onset AD (LOAD).
The onset of FAD is early (< 60 years) and demonstrates an autosomal dominant pattern
of inheritance. The age of onset of LOAD is over 60 years of age and is characterized by
a complex pattern of inheritance. Mutations in three genes, APP, presenilin 1 (PS-1) and
PS-2 are causatively linked with the pathogenesis of FAD by affecting the production of
Aβ (Goate et al., 1991; Selkoe, 1997; Sherrington et al., 1995). The presenilins PS1 and
PS2 most likely, together with three additional subunits (Nicastrin, Anterior pharynx
defective 1 homologue and Presenilin enhancer 2 homologue), provide the catalytic
subunit of γ-secretase (Kimberly et al., 2003) that is involved in processing of APP to Aβ.
Most of the mutations that cause FAD increase production of both Aβ40 and Aβ42 or
selectively increase the production of Aβ42 (Selkoe, 1997). FAD represents less than 1%
of all AD cases.
Goate et al., (Goate et al., 1991) reported first that mutations in APP cause FAD,
followed by identification of 19 missense mutations in this gene to account for a small
portion of FAD cases (about 10%). Most of these mutations occur at the β or γ secretase
cleavage sites. Mutation at γ secretase cleavage site increases the ratio of Aβ42 to Aβ40
(De Strooper and Annaert, 2000), whereas mutation at β secretase cleavage site (Swedish
mutation) results in an increase in total Aβ species without altering the ratio. The PS1
gene contains 12 exons and is located in the long arm of chromosome 14, while PS2 is
located on chromosome 1 and also has 12 exons. After the initial identification of 5
missense mutations on PS-1 by Sherrington et al., (Sherrington et al., 1995), over 130
mutations have been reported accounting for a large proportion of FAD cases. Mutations
in PS1 increase the ratio of Aβ42 to Aβ40 and result in very early onset of AD (26 - 60
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years) (Dawbarn and Allen, 2007). In contrast, only eight FAD mutations have been
identified on PS2 and result in late onset AD (40 – 75 years).
Although a clear picture seems to exist about the genetic risk factors for FAD, the
majority of AD cases are late onset. To date, APOE is the only known genetic risk factor
and has been consistently associated with risk for LOAD in many studies (Finckh, 2003).
Of the three isoforms (APOE2, APOE3, APOE4), the presence of APOE4 increases the
risk in a dose dependent manner. Nearly all individuals homozygous for the APOE4 will
develop AD by 80 years of age (Corder et al., 1993).
ETIOPATHOGENESIS OF AD
Narrowing down to a single unique causative factor for AD pathogenesis is a
challenge, as being a multifactorial disorder well defined genetic factors as well as
numerous potential environmental variables play contributory roles (Welsh, 2006a). For
the naked eye, the brain in cases of AD appears atrophied and externally the brain usually
shows gyral narrowing and sulcal widening, while an increase in ventricular size is
noticed in cerebral slices (Dawbarn and Allen, 2007). Even though the single most
important factor which accounts for the clinical symptoms of AD is loss of neuronal
synapses and neuronal cell death, understanding of the causation of neuronal loss is
confounded by the selective neuronal vulnerability exhibited by the neurons of neocortex
and hippocampus. Characteristically a 40% reduction in the pyramidal neuron density of
neocortex, 68% loss in hippocampal CA1 neurons, 40-70% loss of neurons in basal
nucleus and 40% and 55% loss of neurons in dorsal raphe and locus coeruleus
respectively, have been reported (Arendt et al., 1983; Terry et al., 1981). However, the
exact pathomechanism leading to neuronal death is not clear. As excessive deposition of
Aβ as senile plaques throughout the cerebral cortex is one of the pathological hallmarks
of AD, much effort has been made to understand the mechanisms of AD neuropathology
and the role of APP processing into Aβ. Being one of the key pathological features of
AD, Aβ plaque has been proposed to be a primary cause for neuronal cell loss.
This proposal gained credence by the observations of Aβ plaques surrounded by
degenerating neurons (Katzman and Saitoh, 1991), Aβ peptides being toxic to neurons in
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culture (Aksenov et al., 1998; Varadarajan et al., 1999; Yankner et al., 1989) and the
increased deposition of Aβ due to mutations in APP and presenilin genes. Multiple
mechanisms have been advanced for Aβ induced cell death. They are inflammatory
response and release of neurotoxic cytokines, excessive release of excitatory amino acids
like glutamate from glial cells, inhibition of axonal and dendritic transport and synaptic
dysfunction and loss (Bossy-Wetzel et al., 2004). Though these do not point out precisely
the mechanism of Aβ induced cell death, current literature suggests that one of the main
points of commonality amongst these is that oxidative stress is the mediator of neuronal
death or apoptosis. Mechanisms others than oxidative stress mediating neuronal cell
death have also been under intense investigation, but evidence of oxidative stress in AD
pathology are abundant and compelling.
AD brain is under intense oxidative stress manifested by increased protein
oxidation, lipid peroxidation, increased levels of 4 – hydroxynonenal (HNE) (Lovell et
al., 1997), free radical formation (Butterfield and Lauderback, 2002), increased levels of
isoprostanes (Montine et al., 1998), 3-nitrotyrosine (3NT) levels (Castegna et al., 2003;
Smith et al., 1997), dityrosine (Hensley et al., 1998; Smith et al., 1997), advanced
glycation end products and DNA/RNA oxidation products (Mecocci et al., 1994). The
neurotoxic trace element hypothesis in AD is relevant to the oxidative stress observed in
AD (Markesbery, 1997). Aluminium, mercury and iron have received most attention, of
these, iron (Fe) has the most pathophysiologic role as catalyst for free radical generation.
This is by virtue of its loosely bound electron, ability to exist in more than one valence
state (Markesbery, 1997) and higher levels of Fe in brain (Floyd, 1999). Some of the
reactions that lead to production of oxidants are illustrated in Table 1 [Adopted from
(Welsh, 2006a)]. Aβ, in ways that are inhibited by free radical antioxidants like vitamin
E, cause brain cell protein oxidation, lipid peroxidation and ROS formation, among other
oxidative stress responses, suggesting that this peptide is a source of oxidative stress in
AD brain (Butterfield et al., 2001). The findings that Aβ is central to the pathogenesis of
AD (Selkoe, 2001) and that the AD brain is under significant oxidative stress were united
into a comprehensive model for neurodegeneration in the brain in AD based on Aβassociated free radical generation (Butterfield and Lauderback, 2002).
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Table 1.1 Mechanisms leading to protein oxidation observed in AD, adopted from
Welsh, 2006a
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.
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2TyrOOH
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Schiff base +

HOCl

advanced

OXIDATIVE STRESS
Aerobic organisms use O2 to facilitate the synthesis of energy in the form of ATP
mainly by two routes, glycolysis in cytosol and oxidative phosphorylation on the inner
mitochondrial membrane (Kadenbach, 2003). Oxidative phosphorylation comprises a
respiratory chain consisting of four proton pumps or complexes and produces the
majority of ATP required for the cell. Aerobic organisms use O2 as the terminal electron
acceptor for optimal energy release by mediating the transfer of single electrons (Nohl et
al., 2004) through these complexes. The electrons from reduced substrates are passed
from complexes I and II of the electron transport chain through complexes III and IV to
oxygen, forming water and causing protons to be pumped across the mitochondrial inner
membrane (Brand et al., 2004). As oxygen is predisposed for univalent reductions
(Fridovich, 1999), electrons may leak from the respiratory chain and react inappropriately
with oxygen to form superoxide radical (O2.-). The activity of mitochondrial respiratory
chain complexes, particularly complex I, have been shown to be reduced by the
accumulation of O2.- (Yen et al., 1999; Yen et al., 1996). Superoxide radical can be
considered as the parent radical from which other oxygen radicals and non-radicals are
derived (Nohl et al., 2004). Apart from O2.-, other superoxide derived reactive radicals
include oxygen radicals like hydroxyl radical and peroxyl radicals, and nonradical
molecules like singlet oxygen and hydrogen peroxide (Oberley, 2001), and are
collectively called reactive oxygen species (ROS). A vast majority of cellular ROS,
approximately 90% can be traced back to oxidative phosphorylation in the mitochondria
(Balaban et al., 2005). Initial observations suggested that up to 5% of the total molecular
oxygen utilized by mammalian mitochondria was converted into ROS (Boveris and
Chance, 1973), but more recent analysis estimates about 1-2% to be converted into O2.anion (Cadenas and Davies, 2000). Superoxide and other secondary reactive oxygen
species it generates (Brand et al., 2004) can damage proteins, lipids and DNA directly.
To prevent the detrimental effects of ROS-induced injury, cells are equipped with an
elaborate antioxidant defense system that is comprised of agents that catalytically remove
ROS, agents that decrease ROS formation, proteins that protect biomolecules against
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oxidative damage by other mechanisms, the physical quenching of ROS, the replacement
of molecules susceptible to oxidative damage by molecules resistant to it and the
sacrificial agents that are preferentially oxidized by ROS to preserve more important
biomolecules (Halliwell and Gutteridge, 2007). ROS can also be generated by other
systems existing in endoplasmic reticulum, peroxisomes, intracellular membraneassociated oxidases, plasma membrane-associated oxidases and auto-oxidation of small
molecules like dopamine, epinephrine, flavins and epinephrine (Thannickal and Fanburg,
2000). Any disturbance in the pro-oxidant and anti-oxidant balance in favor of the
former is defined as oxidative stress (Sies, 1985). Brain as a result of consumption of an
inordinate fraction (20%) of the total oxygen consumption for its relatively small weight
(2%), its abundance of easily peroxidizable lipid content (Floyd, 1999), and the relative
paucity of antioxidant enzymes compared to other tissues (Markesbery, 1997), is
especially vulnerable to oxidative stress.
ANTIOXIDANT SYSTEMS
There are three major types of primary interacting (Chow et al., 2002)
intracellular antioxidant enzymes in mammalian cells that can remove ROS: superoxide
dismutase (SOD), catalase (CAT), peroxidase, of which glutathione peroxidase (GPx)
(Oberley, 2001) and peroxiredoxins (Prx) (Halliwell and Gutteridge, 2007) are the most
prominent. The SODs catalyze the dismutation of O2.- into hydrogen peroxide (H2O2) and
molecular oxygen. Hydrogen peroxide is further detoxified by CAT, GPx (Halliwell and
Gutteridge, 1989) and Prx to water. Thus, two reactive species - O2.- and H2O2 are
converted to water (Oberley, 2001) and molecular oxygen. Among the antioxidant
systems, SOD is considered the first line of defense against oxidative stress (Halliwell,
1999; Ho et al., 1998). Three distinct SODs are found in human cells: a homodimeric
cytosolic copper zinc SOD (CuZnSOD) (McCord and Fridovich, 1969), a extra-cellular
homotetrameric glycolsylated CuZnSOD (Marklund, 1982) and mitochondrial matrix
homotetrameric manganese SOD (MnSOD) (Figure 1.2) (Weisiger and Fridovich, 1973).
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Figure 1.2 Scheme for production of superoxide and its detoxification
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MANGANESE SUPEROXIDE DISMUTASE (MnSOD)
MnSOD is a critical antioxidant enzyme in aerobic organisms because under
physiological conditions superoxide is mainly generated on the matrix side of the inner
mitochondrial membrane where MnSOD is located (Balzan et al., 1999) in high
concentrations (Van Remmen et al., 1999). Thus MnSOD can protect mitochondria from
oxidative damage (Van Remmen et al., 1999).
MnSOD from different organisms are homologous and has a manganese ion in the
active site. While Human MnSOD is a homotetramer with identical 24-kd subunits
(Matsuda et al., 1990), E.coli MnSOD is a dimer (Beyer et al., 1991). It is a single-copy
gene consisting of five exons separated by four introns (Wan et al., 1994). The human,
bovine and mouse MnSOD cDNAs share more than 90% similarity (Meyrick and
Magnuson, 1994). The gene is characterized by lack of a TATA or CAAT box and the
presence of a GC-rich region containing SP-1 binding sites (Wan et al., 1994). The
mature protein is strictly a mitochondrial enzyme compartmentalized in the mitochondrial
matrix, although it is encoded by the nuclear sod2 gene, localized in chromosome 6q25
(Matsuda et al., 1990).

Studies performed by us and others have shown that the

imbalance between antioxidants and oxidants leads to various pathological conditions
which can be effectively prevented or alleviated by increased MnSOD (Keller et al.,
1998; St Clair et al., 1991; Yen et al., 1996). The over-all importance of this enzyme is
evident from transgenic animal studies, wherein MnSOD “knock-out” usually dies within
10 days after birth, with cardiac abnormalities, fat accumulation in liver and skeletal
muscle (Lebovitz et al., 1996; Li et al., 1995), and metabolic acidosis (Lebovitz et al.,
1996) with animals surviving longer than 10 days soon succumbing to severe anemia and
neurodegeneration (Melov et al., 1998).

It has been demonstrated that MnSOD

heterozygous knock-out mice show altered mitochondrial function as illustrated by
decreased respiration by complex I and an increase in the sensitivity of the permeability
transition pore induction (Van Remmen et al., 2001), while overexpression of MnSOD
protected complex I inactivation (Yen et al., 1999). Thus, mitochondrial function and
oxidative phosphorylation, necessary machinery for the ATP production in the cell are
likely to be influenced by MnSOD function. Further, recent studies suggest that MnSOD
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plays a protective role during AD development.

For example, MnSOD deficiency

increased β-amyloid levels and amyloid plaque burden, and accelerated the onset of
behavioral alteration in APP transgenic mice (Esposito et al., 2006; Li et al., 2004)
NITRATION OF MnSOD AND NITROTYROSINE IN AD
Post-translation modification like nitration of tyrosine residues present on the
subunits of MnSOD can compromise its activity (Ischiropoulos et al., 1992). Of the nine
tyrosine residues in each subunit of the homotetrameric protein MnSOD, tyrosines 34, 45
and 193 have been shown to be nitrated, with nitration of tyrosine residue 34 causing
inactivation of MnSOD (MacMillan-Crow et al., 1998).

Nitration of

biological

macromolecules can be mediated by nitric oxide, nitrogen dioxide, nitrous acid,
hypochlorous

acid,

nitrated aliphatic

reactive intermediates and peroxynitrite

(Ischiropoulos, 1998). But only peroxynitrite has been demonstrated to nitrate tyrosine
34 of MnSOD leading to its inactivation (MacMillan-Crow et al., 1998; Yamakura et al.,
1998).

Residues 45 and 193 are prone for nitration because of their location with

proximal glutamate residues.

The apparent ability of glutamate residues to direct

peroxynitrite-mediated nitration to specific tyrosine residues is implicated in this situation
(MacMillan-Crow et al., 1998). Even though tyrosine 34 has no proximal glutamate, it is
the most susceptible residue for nitration. This is probably because of its positioning
closest to the active site, only 5 Å from the manganese ion.

The attraction of

peroxynitrite to the active site, by the basic residues in the channel entrance, and its
reaction with manganese ion leading to the formation of nitrating species makes tyrosine
34 more prone for nitration, and thereby inactivating MnSOD (Quijano et al., 2001). The
experiments carried out with E. coli MnSOD, in the absence of manganese ion
demonstrated a reduced nitration on treatment with peroxynitrite suggesting that the
metal center could be involved in nitration possibly by the formation of nitrating species
like nitronium ion or an oxo-manganese complex plus nitrogen dioxide (Quijano et al.,
2001).
NT is a stable adduct involving a carbon – nitrogen bond that is difficult to
remove chemically.

The routes of removing NT in vivo are not yet known, but
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proteolysis is likely to a major route. NT can be excreted in human urine as an amino
acid and as decarboxylated and deaminated products (Beckman, 1996). Tyrosine can be
nitrated by several pathways in vitro; it is a common modification made by protein
chemists to probe the function of tyrosine residues (Beckman, 1996).
In AD, the levels of 3-NT has been shown to be consistently elevated in
hippocampus, neocortical regions and cerebrospinal fluid of AD patients (Hensley et al.,
1998). 3-NT levels correlates positively with decreased cognitive functions (Tohgi et al.,
1999). The formation of 3-NT by addition of a nitro group onto the tyrosine phenols is a
post-translational modification with potentially significant biological implications
(Beckman, 1996; Ischiropoulos, 1998; Smith et al., 1996). The functional consequence of
3-NT formation may be causally linked to pathogenesis of various diseases through
interference of enzyme function, structural protein assembly or modulation of signaling
cascades (Berlett et al., 1998; Estevez et al., 1999; Go et al., 1999; MacMillan-Crow et
al., 1998). Although there is no consensus either about the activity level of MnSOD or
the nitration status of MnSOD in AD, there have been reports of reduction of SOD
activity in AD frontal cortex, hippocampus and cerebellum (Marklund et al., 1985).
Extensive data exist to implicate peroxynitrite as a consistent mediator of 3-NT
formation (MacMillan-Crow et al., 1996; Smith et al., 1996; Yamakura et al., 1998;
Yamamoto et al., 2002). Of relevance to AD is the finding of increased peroxynitrite
production in the synaptosomes exposed to Aβ (Keller et al., 1997). Although one of the
major oxidative modifications of proteins resulting from peroxynitrite is carbonyl
formation from side-chain and peptide-bond cleavage, perhaps the best known property
of ONOO- is its ability to nitrate free tyrosine and tyrosine residues in proteins
(Ischiropoulos et al., 1992; Souza et al., 1999). Importantly, MnSOD, has been shown to
be nitrated and inactivated in chronic rejection of human renal allograft, which was
proposed to be a general mechanism for the amplification of ONOO- mediated oxidative
damage (MacMillan-Crow et al., 1996).

Overall,

the presence of 3-NT has been

suggested to be a signature of peroxynitrite involvement (Smith et al., 1997).
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PEROXYNITRITE
Peroxynitrite has been the subject of intense investigation by researchers loyal to
inorganic peroxide chemistry, radiation, and photochemistry. Since 1990, peroxynitrite
caught the attention of a larger scientific community because of its implications to
biological systems (Beckman et al., 1990). Peroxynitrite is a powerful oxidant and
.

cytotoxic agent formed by the reaction between the free radicals nitric oxide ( NO) and
superoxide (O2.-) at rates approaching diffusion limit – 6.7 x 109 M-1s-1 (Beckman, 1996;
Huie and Padmaja, 1993). As superoxide is short lived and has restricted diffusion across
membranes, peroxynitrite formation has to be spatially associated with the sources of
superoxide (plasma membrane NAD(P)H oxidases or the mitochondrial respiratory
complexes). Nitric oxide produced from cytosolic NOS can diffuse into mitochondria.
This capacity of nitric oxide along with the reports on the presence of nitric oxide
synthase inside mitochondria (Tatoyan and Giulivi, 1998), make the intramitochondrial
formation of peroxynitrite possible. Targets of peroxynitrite inside mitochondria
including MnSOD has been observed (MacMillan-Crow et al., 1996).
In AD brain, nitric oxide can be produced due to activation of inducible nitric
oxide synthase (iNOS) by Aβ surrounding the amyloid plaques (Combs et al., 2001) or
from neuronal nitric oxide synthase (nNOS) induced by Aβ (Stepanichev et al., 2008).
The rate of production of peroxynitrite in vivo in specific compartments has been
estimated to be as high as 50 – 100 μM per minute (Szabo et al., 2007). The short half
life of peroxynitrite (~ 10 ms) is compensated for by its ability to cross cell membranes
with a permeability coefficient comparable to water (Marla et al., 1997). Thus it could
influence surrounding targets cells within one to two cell diameters (~ 5-20 μm).
Externally added ONOO- has been shown to diffuse lipid bilayers passively (Denicola et
al., 1998) over distances of 1 - 10 μm (Radi, 1998).
Peroxynitrite itself is not a free radical because the two unpaired electrons on
superoxide and nitric oxide have combined to form a new bond. Peroxynitrite is a isomer
of nitrate (Beckman, 1996). It is relatively stable in alkaline solution and can be stored in
millimolar concentrations at -80oC for months (Beckman et al., 1994). The biochemistry
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and the reaction of peroxynitrite and/or peroxynitrite-derived with their targets is
illustrated in the Figure 1.3.
Many biomolecules are oxidized and/or nitrated by peroxynitrite/peroxynitrite –
derived species, including tyrosine residues, thiols, DNA and unsaturated fatty-acid
containing phospholipids (Szabo et al., 2007).

3 – nitrotyrosine (3-NT), 3 , 3’ –

dityrosine and 3, 4’ – dihydrophenylalanine are formed by nitration, dimerization and
hydroxylation respectively, by the action of peroxynitrite on tyrosine residues (Radi,
2004).

Apart from tyrosine, cysteine, methionine, phenylalanine are also oxidized

(Beckman and Koppenol, 1996; Ischiropoulos and al-Mehdi, 1995).

Thiols can be

oxidized by one – electron reactions by peroxynitrite-derived radicals (Quijano et al.,
1997). In DNA, purine nucleotides are vulnerable to oxidation and adduct formation,
with 8 – oxo and 8 – nitroguanine being two of the major products. Peroxynitrite is also
capable of causing deoxyribose oxidation and strand breaks (Szabo et al., 2007).
Peroxynitrite-derived radicals react with lipids leading to peroxidation (Radi et al., 1991),
and formation of nitrito-, nitro-, nitrosoperoxo- and/or nitrated lipid oxidation adducts
(Szabo et al., 2007).
ENERGY METABOLISM
ATP is the universal currency for biological energy, and the predominant source
of cellular energy is glucose. Energy is required mainly for three purposes: (1) for the
maintenance of body structure (2) for work activities (3) for thermogenesis (Kadenbach,
2003). ATP can be generated by oxidizing several metabolic fuels, but carbohydrates
and fats are especially important.

ATP is generated from fatty acids after their

conversion to acetyl CoA by beta – oxidation in the mitochondria. Three metabolic
pathways are involved in the production of ATP from fatty acids. These are the beta –
oxidation, Krebs cyle and the respiratory chain. Like that from glucose, the acetyl CoA
formed by beta – oxidation goes through Krebs cycle and respiratory chain to produce
ATP. In brain, the ATP produced from fatty acid is of little value as the activity of
ketoacyl Co-A thiolase, a key enzyme involved in beta – oxidation is 125 times lower
compared to other tissues (Yang et al., 1987). So glucose is the obligatory energy source
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Figure 1.3 Biochemistry of Peroxynitrite: reaction and fate, adopted from Szabo et al., 2007
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for the brain. The ATP from glucose is derived through three major pathways producing
carbon dioxide and water as the end products.

In aerobic organisms, glucose is

metabolized through glycolysis occurring in the cytoplasm, Kreb’s cycle and electron
transport chain in the mitochondria to produce energy in the form ATP.
First process in the utilization of glucose for energy production is glycolysis. In
this process, one molecule of glucose is broken down in a series of ten enzymatically
catalyzed reactions to two molecules of pyruvate. In the priming phase of glycolysis, two
ATPs are utilized to produce fructose 1,6-bisphosphate, followed by the energy
producing phase, where fructose 1,6-bisphosphate is converted stepwise to pyruvate with
the production four molecules of ATP and two molecules of NADH. As two ATP
molecules were consumed in the priming phase, there is a net gain of two ATP
molecules. The overall reaction can be depicted as follows
Glucose + 2 Pi + 2 ADP + 2 NAD+ → 2 Pyruvate + 2 ATP + 2 NADH + 2 H+ + 2 H2O
After the glycolysis takes place in the cell's cytoplasm, the pyruvate molecules
travel into the interior of the mitochondrion. Carbon dioxide is enzymatically removed
from each three-carbon pyruvate molecule to form acetic acid. The enzyme then
combines the acetic acid with an enzyme, coenzyme A, to produce acetyl coenzyme A,
also known as acetyl CoA. Once acetyl CoA is formed, the Krebs cycle begins. This
important step of converting pyruvate to acetyl CoA is catalyzed by the enzyme pyruvate
dehydrogenase (PDH). The Krebs cycle consists of eight steps, catalyzed by various
enzymes, resulting in the production of 2 ATP molecules, 6 NADH molecules, 2 FADH2
and 4 carbon dioxide molecules. The overall reaction is as follows
2 Acetyl CoA + 4 H2O + 6 NAD + 2 FAD → 6 NADH + 2 FADH2 + 4 CO2 + 2 ATP
The electron transport chain comprises of three proton pumps namely, NADH
dehydrogenase or complex I, cytochrome c reductase or cytochrome bc1 complex or
complex III and cytochrome c oxidase or complex IV; and an enzyme complex not
pumping protons – succinate deydrogenase or complex II (Kadenbach, 2003). In addition
to these complexes, two mobile carriers are also involved: ubiquinone, and cytochrome c.
Other key components in this process are NADH/FADH2 and the electrons from them,
hydrogen ions, molecular oxygen, water, and ADP and Pi, which combine to form ATP.
Electron transport chain transfers electrons from NADH and FADH2 to complexes I and
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II respectively through complexes III and IV to oxygen, forming water and causing
protons to be pumped across the mitochondrial inner membrane (Brand et al., 2004).
At the start of the electron transport chain, two electrons are passed from NADH
into the NADH dehydrogenase complex. Coupled with this transfer is the pumping of
one hydrogen ion for each electron.

Next, the two electrons are transferred to

ubiquinone. Ubiquinone is called a mobile transfer molecule because it moves the
electrons to the cytochrome bc1 complex.

Each electron is then passed from the

cytochrome bc1 complex to cytochrome c. Cytochrome c accepts each electron one at a
time. One hydrogen ion is pumped through the complex as each electron is transferred.
The next major step occurs in the cytochrome oxidase complex. This step requires four
electrons. These four electrons interact with a molecular oxygen molecule and eight
hydrogen ions. The four electrons, four of the hydrogen ions, and the molecular oxygen,
are used to form two water molecules. The other four hydrogen ions are pumped across
the membrane. The energy from the transfer of electrons along the chain transports
protons across the membrane and creates an electrochemical gradient. The potential
energy in this gradient is used by ATP synthase to generate ATP from ADP and
inorganic phosphate. The final reaction of electron transport chain is as follows
4 H+ + O2 + 4 e- → 2 H2O
Total ATP produced from electron transport chain is 32, which is as outlined below
1. Each NADH produced in Glycolysis is worth 2 ATP (2 x 2 = 4). In actuality,
NADH is worth 3 ATP, but it costs an ATP to transport the NADH into the
mitochondria, so there is a net gain of 2 ATP for each NADH produced in
glycolysis
2. Each NADH produced in the conversion of pyruvate (2 NADH) to acetyl CoA
and Krebs Cycle ( 6 NADH) is worth 3 ATP so 8 NADH x 3 ATP = 24 ATP
3. Each FADH2 is worth 2 ATP so 2 FADH2 x 2 ATP = 4 ATP
4. 4 from NADH of glycoloysis + 24 from NADH of Kreb’s cycle + 4 FADH2 of
Kreb’s cycle = 32 ATP
Over all, if we add the 4 ATPs produced from glycolysis and Kreb’s cycle (2 each), a
total of 36 ATPs are produced from a single molecule of glucose.
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Under physiological conditions, the amount of ATP supplied by glycolytic pathway is
meager.

But in many tumors having impaired mitochondrial function and thereby

reduced ATP supply from oxidative phosphorylation pathway, there can be up regulation
(faster) of glycolytic capacity. It has been proposed that glycolysis can proceed 100
times faster than respiration, which in turn yield 18-fold more ATP (Bartrons and Caro,
2007), thus acting as a compensatory response for the impaired mitochondrial function.
ALTERED METABOLISM IN AD
As glucose is the obligatory energy source for the brain, its utilization has been
increasingly investigated in AD. AD patients exhibit reduced glucose metabolism in
parietal cortex and temporal gyri when studied longitudinally for one year (Hirono et al.,
2004). Specifically, the reduced activity of pyruvate dehydrogenase complex was
observed as early as 1980 in the cerebral cortex of AD patients (Perry et al., 1980). The
enzymes involved in tricarboxylic cycle also show altered activity in prefrontal cortex of
AD patients (Bubber et al., 2005). In addition to AD patients, transgenic mice Tg2576
exhibiting Alzheimer plaque pathology also show reduced activity of phospho fructo
kinase (PFK) (Bigl et al., 2003). Further, Aβ treated hippocampal neurons have showed
significant decrease in glucose uptake (Prapong et al., 2002). Further, report on nitration
of alpha-enolase, glyceraldehyde-3-phosphate dehydrogenase, ATP synthase alpha chain,
voltage-dependent anion channel – 1 and carbonic anhydrase, enzymes involved in
energy production, in AD brain hippocampus (Sultana et al., 2006) have opened up a new
area of AD research. This alteration of the enzymes involved in energy production is
consistent with that of AD patients having reduced activity of mitochondrial electron
chain components, particularly cytochrome oxidase (Kish et al., 1999; Maurer et al.,
2000). These findings suggest an environment of altered energy production. Decreased
function of electron transport chain components could cause diversion of electrons from
their normal pathway into reaction with molecular oxygen in the neocortex and
hippocampus of AD, resulting in increased superoxide (O2.-) formation, exacerbating the
oxidative stress (Markesbery, 1997).

Thus it is possible that nitration of proteins
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involved in energy production and/or protection of mitochondrial function, may be
responsible for the observed metabolic impairment encountered in AD.
RESEARCH OBJECTIVES
Although, it is documented that, overpression of MnSOD protects against Aβ
induced neurotoxicity, there is no consensus about the activity of MnSOD in AD brain.
In this regard, this dissertation addresses the following hypotheses:
1. MnSOD is nitrated and inactivated in association with Aβ deposition.
To address this hypothesis, in chapter two, a homozygous knock-in APPNLh/NLh x PS1P264L/P264L mouse that simulates a natural progression of Aβ plaque pathology observed
in AD (Reaume et al., 1996) was used to investigate the correlation between Aβ plaque
deposition and nitration of MnSOD. An increased and accelerated deposition of Aβ and
increased levels of Aβ 1-40/ 1-42 along with increased nitration and subsequent
inactivation of MnSOD in association with age, was observed in APPNLh/NLh x PS1P264L/P264L mice.

This change was also associated with impaired mitochondrial

respiration.
2. Nitrative inactivation of MnSOD plays an important role in the impairment
of mitochondrial respiration resulting in alteration of energy metabolism.
This hypothesis is addressed in chapter three, where the SH-SY5Y neuroblastoma cell
line was treated with peroxynitrite to nitrate MnSOD.

MnSOD was nitrated upon

peroxynitrite treatment with an associated decrease in activity.

An impairment of

mitochondrial respiratory function was also observed. Inactivation of MnSOD was an
early

event

in

peroxynitrite-induced

impairment

of

mitochondrial

function.

Mitochondrial dysfunction was ameliorated by SOD mimetic and reproduced by MnSOD
deficiency. The impairment of mitochondrial respiratory function was compensated by
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increased glycolytic activity, which was prevented by SOD mimetic and enhanced by
MnSOD deficiency.

1. The impairment of mitochondrial respiration observed in APP/PS-1 mice
was also associated with an increase in glycolytic activity.

This is addressed in chapter four, where we demonstrate increase in lactate levels,
an indicator of enhanced glycolytic activity and increase in activity of lactate
dehydrogenase in homozygous knock-in APPNLh/NLh x PS-1P264L/P264L mouse. This was
also associated with decrease in pyruvate dehydrogenase activity which can exaggerate
the impaired mitochondrial function.
These results demonstrate a critical role for MnSOD in maintaining mitochondrial
respiratory function and reveal the role of glycolysis in sustaining cellular energy
requirements under pathological conditions associated with MnSOD deficiency.

Copyright © Muthuswamy Anantharman 2008
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CHAPTER TWO
β - AMYLOID MEDIATED NITRATION OF MANGANESE SUPEROXIDE
DISMUTASE
Implication for Oxidative Stress in a APPNLh/NLh X PS-1P264L/P264L Double Knock-In
Mouse Model of Alzheimer’s Disease
ABSTRACT
Alzheimer’s disease is a multifactorial, progressive, age-related neurodegenerative
disease. In familial Alzheimer’s disease, Aβ is excessively produced and deposited
because of mutations in the amyloid precursor protein, presenilin - 1, and presenilin - 2
genes.

Here, we generated a double homozygous knock-in mouse model that

incorporates the Swedish familial Alzheimer’s disease mutations and converts mouse Aβ
to the human sequence in amyloid precursor protein and had the P264L familial
Alzheimer’s disease mutation in presenilin - 1. We observed Aβ deposition in double
knock-in mice beginning at 6 months as well as an increase in the levels of insoluble Aβ140/1-42. Brain homogenates from 3-, 6-, 9-, 12-, and 14-month-old mice showed that
protein levels of manganese superoxide dismutase (MnSOD) were unchanged in the
double knock-in mice compared to controls.

Genotype-associated increases in

nitrotyrosine levels were observed. Protein immunoprecipitation revealed MnSOD as a
target of this nitration. Although the levels of MnSOD protein did not change, MnSOD
activity and mitochondrial respiration decreased in knock-in mice, suggesting
compromised mitochondrial function. The compromised activity of MnSOD, a primary
antioxidant enzyme protecting mitochondria, may explain mitochondrial dysfunction and
provide the missing link between Aβ-induced oxidative stress and Alzheimer’s disease.
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INTRODUCTION
Alzheimer’s

disease

(AD)

is

a

multifactorial,

progressive age-related

neurodegenerative disease that affects more than four million persons in the United States
(Evans et al., 1989). The pathological hallmarks of AD are extracellular Aβ deposits,
neurofibrillary tangles, synaptic loss, and neuronal degeneration.

Aβ plaques are

composed of 40- and 42-mer peptides (Aβ1-40 and Aβ1-42) that are proteolytically
produced from amyloid precursor protein (APP) (Iwatsubo et al., 1994). Three genes,
presenilin 1 (PS-1), PS-2, and APP are causatively linked with the pathogenesis of early
onset familial AD (FAD). The findings that Aβ is central to the pathogenesis of AD
(Selkoe, 2001) and that the AD brain is under significant oxidative stress were united into
a comprehensive model for neurodegeneration in the brain in AD based on Aβ-associated
free radical generation (Butterfield and Lauderback, 2002). The brain in AD has marked
oxidative damage as manifested by increased protein oxidation, lipid peroxidation, free
radical formation (Butterfield and Lauderback, 2002), 3-nitrotyrosine (3-NT) levels
(Castegna et al., 2003; Smith et al., 1997), advanced glycation end products, and
DNA/RNA oxidation products (Mecocci et al., 1994; Nunomura et al., 1999).
Manganese superoxide dismutase (MnSOD) is a homotetramer consisting of
identical 24-kd subunits. The translated precursor in cytosol contains an N-terminal 24amino acid sequence signaling mitochondrial compartmentalization. The mature protein
protects the cells against cytotoxic O2–.. The importance of this enzyme is evident from
MnSOD knockout mice that suffer from a defect of mitochondrial iron-sulfur centers, a
modification proving lethal to newborns (Lebovitz et al., 1996; Li et al., 1995). Activity
of this antioxidant enzyme declines in the aging process (Wei and Lee, 2002). Because
the AD brain is under intense oxidative stress, any dysfunction of MnSOD may lead to
progression of the disease.
Peroxynitrite anion (ONOO–) is a potent biological oxidant that has been
implicated in diverse forms of free radical-induced tissue injury (Wiseman and Halliwell,
1996). Peroxynitrite is produced by the reaction of O2–. and .NO, and this peroxynitrite
can compromise the functional and/or structural integrity of target proteins (Beckman,
1996).

Increased levels of nitrotyrosine (Smith et al., 1997) and 4-hydroxynonenal
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(Montine et al., 1997) are associated with degenerating neurons in AD, suggesting
pathogenic roles of peroxynitrite and membrane lipid peroxidation in this disease.
Mutations in the APP gene and PS - 1 gene lead to increased levels of Aβ, which
appear to contribute to the disease process. One study demonstrated altered levels of Aβ140 and Aβ1-42 distinguish AD from normal aging (Games et al., 1995). Recently, several
transgenic animals have been shown to have increased Aβ peptide deposition and some of
the pathological characteristics similar to AD patients (Wang et al., 1999). Crossing
APP-Tg mutant mice and PS-1-Tg mutant mice resulted in increased Aβ production and
accelerated amyloid deposition in the brains of these animals (Borchelt et al., 1997).
However, increased Aβ levels in these models may, in part, be attributable to an increase
in copy number of the transgene.
The aim of this study was to use a mouse model that resembles the natural
progression of Aβ pathology similar to that observed in AD patients and to gain insight
into potential causes of the mitochondrial alterations that occur during the progression of
AD. The model that we used is a homozygous knock-in APPNLh/NLh X PS-1P264L/P264L
(APP/PS-1) (Reaume et al., 1996; Siman et al., 2000).

The results presented here

demonstrate that these mice have an age-dependent accumulation of Aβ in the brain,
consistent with an increase in both Aβ1-40 and Aβ1-42 and an accelerated decline in
mitochondrial function associated with a decrease in activity of MnSOD because of
nitration. These results suggest a novel Aβ-mediated nitrative inactivation of MnSOD and
inhibition of mitochondrial function in AD.
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MATERIALS AND METHODS
Mutant Mouse Lines
APPNLh/NLh X PS-1P264L/P264L mutant mice were generated using the Cre-lox
knock-in technology (Reaume et al., 1996; Siman et al., 2000).

The APP strategy

introduced the Swedish FADK670N/M671L mutations and changed the mouse sequence
for Aβ to be identical to the human sequence (NLh). These mice demonstrate proper
cleavage of the APP protein to generate the Aβ peptide. The PS-1 mutation targeted
codons 264 and 265 of the mouse PS - 1 gene to introduce the proline to leucine (P264L)
mutation. When PS - 1 mutant mice (P264L) are crossed with the mutant APP mice
(NLh), the mutations are driven by the endogenous promoters of the APP and PS - 1
genes, and expression is limited to the replacement of these two endogenous genes and
not by the expression of multiple transgenes.
Genotyping of Mice
APP/PS-1 mice were maintained on a CD-1/129 background. Wild-type (WT)
mice were obtained from heterozygous APP/PS-1 matings and maintained as a separate
line for use as controls. The APP/PS-1 mutant mice were monitored for maintenance of
the knock-in gene by PCR analysis of tail snip DNA (Reaume et al., 1996). The APP
NLh mutation was screened with primers spanning the loxp sequence in intron 15 of the
targeted

locus

(5'-CACACCAAGAAGTACAATAGAGGG-3'

CCTGGGTTGTAGGGACTGTACTTG-3') (Invitrogen, Carlsbad, CA).

and

5'-

WT mice

showed a single band at 214 bp, whereas the homozygous mutant mice had a single band
at 298 bp. The PS - 1 P264L mutation was identified using primers spanning exon 8 (5'CCCGTGGAGGTCAGAAGTCAG-3'

and

5'-TTACGGGTTGAGCCATGAATG-3')

(Siman et al., 2000) (Invitrogen). WT mice showed a single band at 142 bp, whereas the
homozygous PS - 1 knock-in mutant mice showed a single band at 219 bp. The mice
used in all experiments were either WT or homozygous for APP/PS-1 mutation.
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Immunocytochemistry for Aβ
To determine the deposition of Aβ in APP/PS-1 mice, one brain hemisphere from
3-, 6-, 9-, 12-, and 14-month-old mice was fixed in 4% formaldehyde, processed in the
standard manner, embedded in paraffin, and sectioned at 10-µm thickness. The sections
were deparaffinized, hydrated, and immersed in 88% formic acid for 3 minutes and
washed in distilled water. After blocking with 15% filtered horse serum in automation
buffer (Biomeda Corp., Foster City, CA) for 1 hour at room temperature, the sections
were immunostained with 10D-5 monoclonal antibody (1:100) (NCL-B-amyloid) and a
biotinylated anti-mouse IgG secondary antibody (Vector Laboratories, Burlingame, CA).
The sections were developed using an ABC reagent kit (Vector Laboratories) and
counterstained with hematoxylin.
Tissue Preparation for Aβ Enzyme-Linked Immunosorbent Assay (ELISA)
Cerebral cortices were serially extracted with Tris-buffered saline, pH 7.4,
followed by RIPA buffer [0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate
(SDS), 1% Nonidet P-40, and 5 mmol/L ethylenediaminetetraacetic acid in Tris-buffered
saline] and finally in 70% formic acid. Protease inhibitor cocktail (pepstatin A, leupeptin,
TPCK, TLCK, soybean trypsin inhibitor, 1 µg/ml of each in 5 mmol/L
ethylenediaminetetraacetic acid) was added during Tris-buffered saline and RIPA
extraction. To measure the levels of Aβ1-40 and Aβ1-42, the supernatant obtained from
the SDS extraction step was analyzed by ELISA.
Sandwich ELISA to Determine the Levels of Insoluble Brain Aβ1-40 and Aβ1-42
The sandwich ELISA used here was performed as described previously
(Skovronsky et al., 1998; Suzuki et al., 1994; Turner et al., 1996), and the absorbencies
falling within the standard curve for each assay were converted to pmol. The sandwich
ELISA consisted of a capture monoclonal antibody (mAb, BAN50) that was specific for
the first 10 amino acids in Aβ and was used in conjunction with one of two different
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detection antibodies, BA27 mAb specific for Aβ species ending at amino acid 40 or BC05
mAb specific for Aβ species ending at position 42(43). This ELISA had a detection limit
of 3 to 6 fmol/well for Aβ1-40 and 1-42/43. The mAbs BAN50, BA27, and BC05 were
prepared as described previously, and each ELISA result was normalized for the dilution
and tissue weight (pmol/µg wet tissue).
Mitochondrial Isolation
Mice were euthanized; brains (excluding cerebellum) of three mice from each age
group were pooled, homogenized in 5 ml of ice-cold mitochondrial isolation buffer
containing 0.225 mol/L D-mannitol, 0.075 mol/L sucrose, 20 mmol/L HEPES, 1 mmol/L
EGTA, and 1% bovine serum albumin, pH 7.2, in a Dounce homogenizer with a glass
pestle. The homogenized brains were then diluted with isolation buffer to a final volume
of 10 ml, centrifuged at 1500 x g for 5 minutes. The supernatant was kept on ice, and the
pellet resuspended in 3 ml of isolation buffer, homogenized, and centrifuged at 1500 x g
for 5 minutes. The supernatants were combined and centrifuged at 13,500 x g for 10
minutes. The brown mitochondrial pellets were resuspended in 100 µl of isolation buffer
and kept on ice, and the protein concentration was determined by Bradford assay.
Measurement of Mitochondrial Respiration
Mitochondrial proteins were resuspended in buffer containing 0.25 mol/L sucrose,
50 mmol/L HEPES, 2 mmol/L MgCl2, 1 mmol/L EGTA, 10 mmol/L KH2PO4, and 0.5%
bovine serum albumin, pH 7.4. Oxygen consumption was measured using a Clark-type
electrode oxygraph (Hansatech Inc., Norfolk, UK) with 10 mmol/L pyruvate and 5
mmol/L malate as substrate in the absence of exogenous ADP (state 2 respiration) and
after addition of 300 mmol/L ADP (state 3 respiration).

The ATPase inhibitor

oligomycin (100 µg/ml) was then added to inhibit mitochondrial respiration. In normally
coupled mitochondria, the addition of oligomycin slows respiration to a rate similar to
that of state 2, whereas in uncoupled mitochondria oligomycin inhibition is reduced.
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Respiratory control ratio (RCR) was calculated as the ratios between state 3 and state 2
respirations.
Immunoprecipitation
Isolated mitochondrial protein (200 µg) was resuspended in 200 µl of RIPA buffer
(9.1 mmol/L Na2HPO4, 1.7 mmol/L NaH2PO4, 150 mmol/L NaCl, 0.5% sodium
deoxycholate, 1% v/v Nonidet P-40, and 0.1% SDS, pH 7.2). Polyclonal nitrotyrosine
antibody (anti-rabbit, 2 µg/ml; Cayman Chemical, Ann Arbor, MI) was added and
incubated overnight at 4°C. Protein A/G agarose (20 µl) (Santa Cruz Biotechnology,
Santa Cruz, CA) was added to the mixture and incubated overnight. Immunocomplexes
were collected by centrifugation at 1000 x g for 5 minutes at 4°C, followed by washing
with RIPA buffer, four times. Immunoprecipitated samples were recovered by
resuspending in 2X sample loading buffer, immediately fractionated by reducing
SDS/polyacrylamide gel electrophoresis (PAGE), and analyzed by Western blot.
Western Blot Analysis
Equal amounts of brain homogenated proteins were resuspended in 2X sample
loading buffer and separated on 12.5% SDS-PAGE. After separation by SDS/PAGE
proteins were transferred electrophoretically to nitrocellulose membranes (Schleicher &
Schuell, Dassell, Germany) and blocked with 5% nonfat dried milk in 50 mmol/L Tris,
pH 7.9, 150 mmol/L NaCl, and 0.05% (v/v) Tween-20. After blocking, the blots were
incubated overnight at 4°C with appropriate primary antibody (rabbit, anti-MnSOD IgG,
dilution 1:10,000; Upstate Technology, Lake Placid, NY), followed by incubation with
horseradish peroxidase-conjugated anti-rabbit secondary antibody. Probed membranes
were washed three times, and immunoreactive proteins were detected using enhanced
chemiluminescence (Amersham Corp., Piscataway, NJ).
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MnSOD Activity Assay
SOD activity in the homogenized brain sample was measured by the nitro blue
tetrazolium (NBT)-bathocuproine sulfonate reduction inhibition method (Spitz and
Oberley, 1989). This is an assay based on the competition reaction between SOD and the
indicator molecule NBT. When increasing amounts of protein (containing SOD activity)
were added to the system, the rate of NBT reduction was progressively inhibited.
Potassium cyanide at 5 mmol/L was used to inhibit Cu/ZnSOD and thus measured only
MnSOD activity.

The assay mixture also contained catalase to remove H2O2 and

diethylenetriaminepentaacetic acid to chelate metal ions capable of redox cycling and
interfering with the assay system. One unit of SOD activity was defined as the amount of
SOD protein that caused a 50% reduction in the background rate of NBT reduction.
Statistical Analysis
Statistical significance was analyzed by two-way analysis of variance, followed
by Newman-Keuls multiple comparison test when applicable. The experiments were
repeated at least three times, and the graphs were drawn using Graph Pad Prism, version
3.02.
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RESULTS
Aβ Deposition in APP/PS-1 Mice
To determine the deposition of Aβ, we examined brain sections that were
immunostained with 10D-5 antibody. The brains from WT mice contained no plaques at
any age. The APP/PS-1 animals showed no deposition of Aβ at the age of 3 months
(Figure 2.1A). At the age of 6 months (Figure 2.1B), a few microscopic, scattered, small
Aβ plaques were found in the frontal cortex. By 9 months (Figure 2.1C) there were a few
larger Aβ plaques and more scattered smaller Aβ deposits. By 12 months (Figure 2.1D),
Aβ deposition was more prominent in the neocortex and spread of plaques to the
hippocampus occurred, with many larger confluent Aβ plaques and many small and
moderate size plaques. By 14 months, there were larger numbers of Aβ deposits and Aβ
in small blood vessel walls in brain and leptomeninges (Figure 2.1E). These results
suggest that there was an age-related, regional dependence to Aβ deposition in APP/PS-1
mice.
Increased Levels of Aβ1-40 and 1-42 Fractions in APP/PS-1 Mice
The accumulation of diverse species of Aβ peptides in amyloid plaques is a
multistep process including the conversion of soluble Aβ into insoluble derivatives that
assemble into amyloid fibrils and aggregate in extracellular deposits (Games et al., 1995).
We examined whether the APP/PS-1 mice model showed an increase in levels of SDSsoluble fractions of Aβ1-40 and 1-42 in cerebral cortical tissue. APP/PS-1 mice exhibited
a trend of age-related increase in the load of both species of Aβ (Figure 2.2A & B).
Unchanged MnSOD Protein Levels in WT and APP/PS-1 Mice
Expression of MnSOD is highly inducible by oxidative stress-inducing agents. To
determine whether increases in Aβ produced increases in MnSOD enzyme levels,
Western blot analyses of brain homogenate from animals of different ages of both WT
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Figure 2.1 Age-related Aβ deposition in the brains of APP/PS-1 mice
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Figure 2.1 Age-related Aβ deposition in the brains of APP/PS-1 mice. Sections of
frontal cortex from APP/PS-1 mice immunostained with 10D-5 antibody
for Aβ.
A. 3-month old animal showing no amyloid immunostaining in cortex.
B. 6-month old mouse showing rare small deposits of Aβ (arrows).
C. 9-month old mouse showing increased Aβ deposits.
D. 12- month old mouse demonstrating numerous variable size deposits of Aβ.
E. 14-month old mouse showing numerous diffuse Aβ deposits in cortex.
F. 14-month old mouse demonstrating many Aβ deposits in cortex in parenchymal and
leptomeningeal vessels (arrows). Original magnifications, ×100.
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Figure 2.2 Increased levels Aβ1-40 and 1-42 fractions in APP/PS-1 mice.
Aβ1-40 and Aβ1-42 levels were measured by ELISA from different groups (n = 5/group)
as described in Materials and Methods section. Both species of Aβ showed an increasing
trend in the levels associated with age (R2 = 0.8072 for Aβ1-40 and 0.702 for Aβ1-42).
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and APP/PS-1 mutant mice were performed. The protein levels of MnSOD did not
change when compared between genotypes or between different ages within a genotype
(Figure 2.3A & B).
Increased Nitration of MnSOD in APP/PS-1 Mice
MnSOD is susceptible to peroxynitrite-induced inactivation (MacMillan-Crow et
al., 1996).

To determine whether Aβ-induced oxidative stress was associated with

nitration and inactivation of MnSOD, nitration of MnSOD was detected by Western blot
analysis

of

SDS/PAGE-fractionated mitochondrial

proteins,

which

had

been

immunoprecipitated using a polyclonal anti-nitrotyrosine antibody. Immunodetection
with polyclonal anti-MnSOD demonstrated detectable levels of nitrotyrosine in WT mice
at all ages tested. In contrast, the APP/PS-1 mice showed an increasing trend in the level
of immunoreactive-nitrated MnSOD (Figure 2.4A & B), but the increase was not
statistically significant at p < 0.05. The increase was significant when compared between
the two genotypes (p < 0.01).
Decreased SOD Activity in APP/PS-1 Mice
MnSOD catalyzes the dismutation of superoxide to hydrogen peroxide and
molecular oxygen, and this conversion was used to estimate the activity of MnSOD. The
activity of MnSOD in APP/PS-1 mice was significantly decreased (p < 0.0001) when
compared to the WT mice. WT mice showed a significant (**p < 0.05) decrease in
MnSOD activity at 12 and 14 months when compared to 3-month-old mice of their own
genotype (Figure 2.4C). There was also a significant decrease (*p < 0.05) in activity of
MnSOD in APP/PS-1 mice when compared to their age-matched WT controls (Figure
2.4C).
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Figure 2.3
Unchanged MnSOD protein levels in WT and APP/PS-1 mice.
Representative (out of three) immunoblot (A) and densitometry analysis (B) showing the
levels of MnSOD. Protein (30 μg) extracted from brain specimens of APP/PS-1 knock-in
and wild type mice were run on a 12.5% SDS-polyacrylamide gel electrophoresis. Protein
levels of MnSOD did not show significant age and genotype associated alterations. β-actin
was used to normalize protein loading. WT – Wild type; HO – APP/PS-1.
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Figure 2.4 Increased nitration and decreased activity of MnSOD in APP/PS-1 mice
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Figure 2.4 Increased nitration and decreased activity of MnSOD in APP/PS-1 mice.
Immunoprecipitation of nitrotyrosine with MnSOD. Isolated mitochondrial
protein (200 µg) was precipitated with polyclonal nitrotyrosine antibody and
analyzed by Western blotting using MnSOD antibody
A. Nitrotyrosine coimmunoprecipitated with MnSOD showed that MnSOD is nitrated. WT –
Wild type; HO – APP/PS-1; Positive control – Brain homogenate + Peroxynitrite (2 µM),
provided by Dr. Timothy R. Miller, Graduate Center for Toxicology, University of
Kentucky, Lexington, Kentucky; Pellet – Pellet of the isolated mitochondrial protein (200
µg) precipitated with pre-immune IgG, analyzed by Western blotting using MnSOD
antibody; Supernatant of the isolated mitochondrial protein (200 µg) precipitated with
pre-immune serum, analyzed by Western blotting using MnSOD antibody
B. Densitometric analysis and subsequent statistical analysis by 2-way ANOVA showed
significant differences (*, p < 0.01) when compared between genotypes.
C. MnSOD activity in the brain specimen was measured by the nitroblue tetrazolium (NBT)bathocuproine sulfonate (BCS) reduction inhibition method.26 Statistical analysis by 2way ANOVA showed significant age- and genotype-dependent decreases (p < 0.0001) in
activity of MnSOD. APP/PS-1 mice, at all ages, showed significant decreases (*, p <
0.05) in MnSOD activity when compared with age-matched WT mice. WT mice at 12and 14-months showed significant decrease (**, p < 0.05) in MnSOD activity when
compared with 3-month old WT mice. Immunoprecipitation and MnSOD activity was
carried out in three sets of animals.
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Decreased Mitochondrial Respiration in APP/PS-1 Mice
MnSOD is a primary antioxidant enzyme protecting mitochondria from oxidative
injury. To determine whether a reduction of MnSOD activity would affect mitochondrial
respiratory function, oxygen consumption by isolated mitochondria was measured as an
indicator of the mitochondrial respiration activity. Pyruvate and malate were used as
substrates to determine the function of brain mitochondria from WT and APP/PS-1 mice
via complex I respiration.

The results showed that the RCR of mitochondria was

significantly (*p < 0.01) decreased in 9- and 12-month-old APP/PS-1 mice when
compared to age-matched WT mice and also when compared to 3-month-old mice of both
genotypes (**p < 0.001) (Figure 2.5). The results suggest that in APP/PS-1 mice there is
inhibition of NAD-linked state 3 respiration rate, which is mediated through complex 1 of
the mitochondrial electron transport chain.

WT mice showed a small decrease in

mitochondrial respiration with age; however, it was not statistically significant.
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Figure 2.5 Decline in mitochondrial respiration via complex I in APP/PS-1 mice.
Oxygen consumption was measured using a Clark-type electrode oxygraph. Respiratory
control ratio (RCR) was calculated as the ratios between state 3 and state 2 respirations.
APP/PS-1 mice at 9 and 12 months of age showed a significant decrease (*, p < 0.01) in
mitochondrial respiration when compared to its age-matched WT mice and a significant
decrease (**, p < 0.001) compared to 3-month old mice of both genotypes. Statistical
analysis – two-way ANOVA followed by Newman-Keuls multiple comparisons test.
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DISCUSSION
Numerous reports have described attempts to recapitulate the hallmark
pathologies of AD in the rodent brain by overexpression of human APP or APP
fragments in transgenic models (Games et al., 1995; LaFerla et al., 1995; Lamb et al.,
1993); examples include, Tg2576 mice that overexpress human APP695 (Hsiao et al.,
1996) with Swedish FAD mutations, mice obtained by crossing Tg2576 mice and
transgenic PS1-P264L mice (Holcomb et al., 1998; McGowan et al., 1999), and the
crosses of other Swedish APP transgenic mice with transgenic FAD mutant PS-1 mice
(Borchelt et al., 1997). In this study, we used a double gene-targeted APPNLh/NLh/PS1P264L/P264L mouse model for amyloid deposition without the overexpression of APP
(Flood et al., 2002).
Humanization of the mouse Aβ gene sequence results in an approximate threefold
increase in amyloidogenic processing of recombinant APP in rat hippocampal neurons
infected with Semliki Forest virus expression constructs (De Strooper et al., 1995), and
single mutant PS-1 allele was sufficient to elevate the concentration of Aβ42 in brain and
speed the onset of amyloid deposition and reactive astrogliosis (Siman et al., 2000). Our
results using mice homozygous for APP/PS-1, which completely lack WT APP or PS-1
and expressed both mutant FAD APP and PS-1 at natural levels, showed age-dependent
increases in amyloid pathology (Figure 2) in accordance with the results obtained from
APP 695SWE transgenic mice having PS-1 P264L knock-in mutation (Flood et al., 2002;
Siman et al., 2000). The observed accelerated Aβ deposition in APP/PS-1 mice also
seems to have region dependence in relation to age, with deposition seen first in frontal
cortex and later encompassing other cortical regions and hippocampus.

Thus, this

humanized mouse model should serve as a useful model to study the Aβ-induced
pathology in human AD.
Measurement of Aβ1-40 and 1-42 showed that there was an increasing trend in
both species in APP/PS-1 mice. Our findings are in concordance with that of Wang and
colleagues who demonstrated an increase in average levels of Aβ1-40 and Aβ1-42 in AD.
Our finding of increased quantity of Aβ1-40 and Aβ1-42, is consistent with the possibility
that Aβ1-42 serves as the initial seeding event for plaque formation and that increased
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levels of Aβ1-40 play a role in growing plaques and may be mechanistically linked to the
onset and progression of AD (Wang et al., 1999).
The AD brain is under pronounced oxidative stress, as manifested by protein
oxidation, lipid peroxidation, DNA and RNA oxidation, widespread peroxynitriteinduced damage, advanced glycation end products, and altered antioxidant enzyme
expression. Via mechanisms that are inhibited by antioxidants such as vitamin E, Aβ
causes brain cell protein oxidation, lipid peroxidation, and ROS formation, among other
oxidative stress responses, suggesting that this peptide is a source of oxidative stress in
the brain (Butterfield et al., 2001). Other sources of oxidative stress in AD are likely,
ranging from altered mitochondrial function, trace metal ion imbalances to binding of
altered metal ion to biomolecules (Markesbery, 1997). Our results indicating increased
nitration of MnSOD protein signify an increase in oxidative stress in the brain of the
APP/PS-1 mice and suggest a compromise in mitochondrial function of APP/PS-1 mice
attributable to increased oxidative stress.
The mitochondrion, a major subcellular source of ROS (Dugan et al., 1995) plays
a pivotal role in apoptosis (Piantadosi and Zhang, 1996). However, the mitochondrion is
also a site of cellular protection against ROS that involves an elaborate antioxidant
defense system, especially MnSOD. Our studies indicate that the expression pattern of
MnSOD in APP/PS-1 mice remained unaltered in all age groups, but SOD activity in
APP/PS-1 mice was significantly reduced when compared to age-matched WT mice,
suggesting that the protein was inactivated. Our finding is in accordance with that
reported by Macmillan-Crow and colleagues (MacMillan-Crow et al., 1996) in a chronic
rejecting renal model. The decreased activity of MnSOD is attributable to nitration of
tyrosine residues (Smith et al., 1996; Smith et al., 1997) that occurs on the MnSOD
protein. Tyrosine nitration (3-nitrotyrosine, 3-NT) is an in vivo posttranslational protein
modification with potentially significant biological implications (Beckman, 1996;
Ischiropoulos, 1998) and has been detected in a number of human and animal models of
disease (Kroemer et al., 1997). 3-NT is increased in the hippocampus and cerebral cortex
of aged rats (Shin et al., 2002), the cerebrospinal fluid of aged humans (Tohgi et al.,
1999), and the subcortical white matter of aged monkeys (Sloane et al., 1999). 3-NT
formation is the hallmark of reactive peroxynitrite (ONOO–), and this modification can
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compromise the functional and/or structural integrity of target proteins (Smith et al.,
1996), especially MnSOD (Ischiropoulos et al., 1992). After diffusing into mitochondria,
.

NO can inhibit oxygen consumption by complex IV. Inhibition by .NO is reversible;

however, this process decreases electron transport and could potentially increase the
concentration of O2–. (MacMillan-Crow et al., 1996). MnSOD has a function to eliminate
O2–. from the mitochondrial matrix space. But, the concentration of .NO required to
inhibit complex IV is sufficient to compete effectively with MnSOD for O2–. by a rapid
reaction generating peroxynitrite, which can nitrate tyrosine residues and inactivate
MnSOD to increase further the intramitochondrial level of O2–. (MacMillan-Crow et al.,
1996). O2–. reacts with .NO faster than with MnSOD (Hsu et al., 1996); therefore, if
mitochondria contain inactive MnSOD, this peroxynitrite can further nitrate MnSOD and
inactivate MnSOD to increase the intramitochondrial level of superoxide. Consequently
this peroxynitrite-mediated amplification cycle would result in a progressive increase of
mitochondrial levels of peroxynitrite, which can induce additional cytotoxic effects
(MacMillan-Crow et al., 1996) including inactivation of complexes I and II in the
mitochondrial respiratory chain (Cassina and Radi, 1996).
Myeloperoxidase (MPO), one of the principle hemoproteins stored in the
azurophilic granules of neutrophils and monocytes, is also a catalyst of nitrotyrosine
formation via nitrite oxidation to the potent nitrating species nitrogen dioxide (.NO2)
(Baldus et al., 2001). It has been demonstrated in vascular tissues that MPO significantly
contributes to nitrotyrosine formation in vivo (Baldus et al., 2002; Baldus et al., 2001).
Further, it has been shown that MPO

–/–

animals have reduced nitrotyrosine

immunoreactivity than WT mice (Baldus et al., 2002). MPO is not only present in
neutrophils and monocytes, but also in microglia. Microglia are quiescent in normal
brain but can become activated in response to neuronal damage or various other stimuli,
including aggregated Aβ (El Khoury et al., 1998; Meda et al., 1995). In AD, MPO has
been shown to be co-localized around the Aβ plaques and also in microglia-macrophages
that are present around the plaques. It has also been shown that Aβ treatment of the
mouse microglia cell line BV-2 resulted in strong induction of MPO mRNA expression
(Reynolds et al., 1999). From these observations and the fact that senile plaques are
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surrounded by activated microglia, it can be cautiously speculated that MPO may also
contribute to the nitration of MnSOD.
Despite major advances in the study of nitration of proteins, the effect of nitration
on protein turnover and the pathways that degrade the nitrated proteins have not been
fully elucidated. There are reports about faster degradation of proteins treated with
peroxynitrite or a generator of nitric oxide and superoxide by 20S proteasome (Grune et
al., 1998). Consistent with this, Souza and colleagues (Souza et al., 2000) reported that a
single nitrating event is sufficient to target proteins for degradation by the proteasome.
Although protein nitration is generally viewed as an irreversible event, activities that
appear to specifically repair nitrated proteins have been reported in human and rat tissues
(Gow et al., 1996; Kamisaki et al., 1998). Thus it tempting to speculate that nitration of
MnSOD may be reversible. In this regard, our APP/PS-1 mouse model is ideal for testing
pharmacological intervention by mitochondrially targeted antioxidants such Mito-Q or
Mito-Vit E.
Mito-Q [mixture of mitoquinol-10-(6'-ubiquinolyl)de-cytriphenylphosphonium
and mitoquinone-10-(6'-ubiquinonyl)decyltriphenylphosphonium] (Kelso et al., 2001)
and MitoVit E [2-[2-(triphenylphosphonio)ethyl]-3,4-dihydro-2,5,7,8-tetra-methyl-2H-1benzopyran-6-ol bromide] have been found to destroy superoxide in the mitochondrial
matrix (Echtay et al., 2002). Mito-Q (Mito-Q10) has been shown to be an effective
antioxidant against lipid peroxidation, peroxynitrite, and superoxide (James et al., 2005).
Pretreatment with Mito-Q and Mito Vit-E have been shown to 1) significantly abrogate
the lipid peroxide-induced 2'-7'-dichlorofluorescein fluorescence and protein oxidation in
bovine aortic endothelial cells; 2) inhibit cytochrome c release, caspase-3 activation, and
DNA fragmentation; 3) inhibit H2O2 and lipid peroxide-induced inactivation of complex I
and aconitase, thus preventing the production of superoxide; 4) inhibit TfR
overexpression and mitochondrial uptake of
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Fe, thereby inhibiting apoptosis; and 5)

restore the mitochondrial membrane potential and proteasomal activity (Dhanasekaran et
al., 2004). Further, the pro-oxidant effect or superoxide production by Mito-Q10 was
found to be insufficient to cause any damage but led to hydrogen peroxide production and
nitric oxide consumption (James et al., 2005). Despite these results, the effect of these
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compounds on the reversal of damage that has already been caused by oxidative stress has
not been investigated.
The antioxidant efficacy of Mito-Q10 is due to its conversion to ubiquinol by
complex II of the mitochondrial respiratory chain, but its reoxidation back to ubiquinone
by complex III is ineffective. In ubiquinol form, Mito-Q10 quenches ONOO– and becomes
oxidized, which can be reduced by complex II to ubiquinol, making it available to quench
more ONOO– (James et al., 2005). Mito-Q10 may be effective in preventing the nitration
of MnSOD and may serve as an effective therapeutic intervention to slow the progression
of AD.
Mitochondrial respiratory dysfunction and oxidative stress have been associated
with many neurodegenerative diseases (Beal, 1995). Results obtained in this study on
mitochondrial respiration using pyruvate plus malate as substrate demonstrate that in
APP/PS-1 mice there is inhibition of NAD-linked state 3 respiration rate, which is
mediated through complex 1 of the mitochondrial electron transport chain.

RCR

represents functional integrity of isolated mitochondria (Yen et al., 1999). A high value
of RCR indicates the utilization of substrates is tightly coupled to the production of ATP.
The respiration injury would predict a low coupling efficiency of the mitochondrial
electron transport and an increased likelihood of electron leakage during respiration,
leading to O2–. radical formation and increased oxidative stress. Our finding is consistent
with that of Kokoszka and colleagues (Kokoszka et al., 2001) who reported a decrease in
state III respiratory states and the RCR of liver mitochondria from both homozygous and
heterozygous knock-out mice for the gene encoding the MnSOD protein, sod 2. Cardiac
mitochondria from sod 2 +/– mice, which have 50% reduction in MnSOD activity, showed
altered mitochondrial function as exemplified by decreased respiration by complex I and
an increase in the sensitivity of the permeability transition pore induction (Van Remmen
et al., 2001). Thus, mitochondria from the heart (sod 2 +/–) and liver (sod –/– and sod2 +/–)
show evidence of increased oxidative damage compared with mitochondria isolated from
sod2

+/+

mice. Yen and colleagues (Yen et al., 1999) showed that MnSOD selectively

protected state 3 respiration activity through complex I substrates and prevented
complex I inactivation in heart mitochondria treated with the anthracyclin antibiotic,
adriamycin. These results indicate that MnSOD plays a critical role in oxidative stress
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responses and in maintenance of mitochondrial respiration and the lack or reduced
activity that leads to increased sensitivity of the animals to oxidative stress-induced
mitochondrial damage. The decreased activity of MnSOD in APP/PS-1 mice can be
implicated as a cause of decreased state 3 respiration rate seen in these mice. Our study,
which shows a decline in mitochondrial respiration in aged (9 and 12 months) WT mice,
also implicates the effects of mitochondrial ROS production in the process of aging. Our
findings are consistent with studies that demonstrate a decline in respiratory function of
mitochondria with age (Wei and Lee, 2002; Yen et al., 1989) and decreased
mitochondrial respiratory function in aged or aging mice, due to deficiencies in the
MnSOD (Kokoszka et al., 2001). Our results also suggest that nitrative inactivation of
MnSOD may be, at least in part, responsible for the decline in the mitochondrial function
of aging AD mice. Biochemical analyses of brain specimens from patients with AD have
shown abnormalities in the components of electron transport chain, particularly in the
activity of cytochrome oxidase (COX) (Kish et al., 1999; Maurer et al., 2000). Inhibition
of COX could cause depressed ATP synthesis and bioenergetic impairment in AD. In
addition, the decreased COX function could cause diversion of electrons from their
normal pathway into reaction with molecular oxygen in the neocortex and hippocampus
in AD, resulting in increased O2–.(Markesbery, 1997). Superoxide can contribute to
mitochondrial impairment by generating additional reactive species, particularly hydroxyl
radical, and peroxynitrite that can inactivate mitochondrial proteins leading to further
decline in mitochondrial respiration, decreased ATP production, and ultimately neuronal
cell death (Eckert et al., 2003).
Although there is no consensus about the activity level of MnSOD in AD, there
have been reports of reduction of SOD activity in AD frontal cortex, hippocampus, and
cerebellum (Richardson, 1993) and elevation of SOD activity in the caudate nucleus of
AD (Marklund et al., 1985).

However, there are reports of increased nitrotyrosine

immunoreactivity in neurons of AD (Good et al., 1996; Vodovotz et al., 1996). To our
knowledge the identity of the nitrated proteins in the AD brain is not known. Our results
showing decreased activity of MnSOD in relation to age and nitration represents the first
study directed to the identification of nitrated proteins in AD brain.
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The mouse model used in our study has the sequence of Aβ identical to the human
sequence. Further, the mutations introduced are driven by endogenous promoters of APP
and PS-1 genes, and expression is limited to the replacement of these two endogenous
genes and not by the expression of multiple transgenes. The amyloid pathology observed
in this model is similar to that found in AD. Thus, the results obtained from this model
may prove useful in unraveling the pathogenesis of AD-induced oxidative stress.
In conclusion, in this study we demonstrate an increased and accelerated
deposition of Aβ in APP/PS-1 mice, increased levels of Aβ1-40/1-42, increased
nitrotyrosine and subsequent inactivation of MnSOD, and impaired mitochondrial
respiration in APP/PS-1 mice in association with age. The increased levels of Aβ1-40/142, essential for aggregation and subsequent neurotoxic properties, are observed from 6
months on. It is tempting to speculate that the increased Aβ may be the cause of
alterations seen in MnSOD and the associated decrease in mitochondrial function. These
changes may lead to altered function of mitochondrial permeability transition pore (Yen
et al., 1989), which increases the propensity to undergo apoptosis. This is important
because findings indicate that neuronal cell death associated with Aβ peptide are
apoptotic in nature (Dickson, 2004). Thus, our studies which indicate mitochondrial
dysfunction, an age-associated increase in nitration of MnSOD, and its concomitant
decrease in antioxidant activity, may provide the missing link between Aβ-induced
oxidative stress and progression of AD.

Copyright © Muthuswamy Anantharman 2008
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CHAPTER THREE
PEROXYNITRITE INDUCED NITRATION OF MnSOD REVEALS A NOVEL
MECHANISM FOR THE REGULATION OF METABOLIC SWITCH IN
NEURONAL CELLS
ABSTRACT
The energy demand of a cell is met predominantly by oxidative phosphorylation
and glycolysis, both capable of mutual compensation.

Because the mitochondrial

electron transport chain can generate superoxide radicals during the process of ATP
production, which leads to mitochondrial dysfunction, we investigated whether
inactivation of Manganese superoxide dismutase (MnSOD), a critical antioxidant enzyme
in mitochondria, would lead to an increase in glycolysis for ATP production. Here we
report that exposure of SH-SY5Y cells to 250 μM peroxynitrite treatment leads to
MnSOD nitration and subsequent reduction in activity. MnSOD activity was inactivated
at a concentration of peroxynitrite 10 times lower than that required to inhibit
mitochondrial respiration. Compromised mitochondrial function was demonstrated by
the reduced activity of complex I and inhibition of MTT reduction.

The loss of

complex I activity was alleviated by SOD mimetic and was reproduced by MnSOD
siRNA. The decline in mitochondrial function of peroxynitrite treated cells did not result
in decreased ATP levels but was accompanied by an up-regulated glycolysis signified by
high levels of lactate and lactate dehydrogenase activity but decreased activity of
pyruvate dehydrogenase.

These changes were reversed by SOD mimetic and were

promoted by MnSOD siRNA, linking the effect of reduced MnSOD activity to a switch
in the cell’s energy production mechanism. Specific reduction of MnSOD in MnSOD
heterozygous knock-out mice led to decreased RCR and complex I activity with
increased lactate levels, further supporting the role of MnSOD in regulating energy
metabolism switch. Our results suggest that glycolysis plays a role in sustaining cellular
energy requirements under pathological conditions with MnSOD deficiency.
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INTRODUCTION
Aerobic organisms use O2 to facilitate the synthesis of energy in the form of ATP
mainly by two routes, glycolysis in cytosol and oxidative phosphorylation in the inner
mitochondrial membrane (Kadenbach, 2003). Oxidative phosphorylation comprises a
respiratory chain consisting of three proton pumps or complexes and produces the
majority of ATP that cells require. Aerobic organisms use O2 as a terminal electron
acceptor for optimal energy release by mediating the transfer of single electrons (Nohl et
al., 2004) through these complexes. The electrons from reduced substrates are passed
from complexes I and II of the electron transport chain through complexes III and IV to
oxygen, forming water and causing protons to be pumped across the mitochondrial inner
membrane (Brand et al., 2004). But in circumstances of energy deficiency caused by
compromised mitochondrial function, enhanced glycolytic capacity exists, even in the
presence of high O2 concentration (Pedersen, 2007; Schoonen et al., 1990; Warburg,
1956; Wu et al., 2007). Mitochondrial dysfunction can occur due to accumulation of
oxygen-derived reactive species such as hydroxyl radical and peroxyl radicals, and
nonradical molecules such as singlet oxygen and hydrogen peroxide (Oberley, 2001),
collectively called reactive oxygen species (ROS). ROS are formed by the nature of
oxygen, which is predisposed for univalent reductions (Fridovich, 1999). Electrons can
leak from the respiratory chain and react with oxygen to form superoxide radicals (O2.-).
Thus, superoxide radicals can be considered the parent radical from which other oxygen
radicals and non-radicals are derived (Nohl et al., 2004). Approximately 90% of cellular
ROS can be traced to oxidative phosphorylation in mitochondria (Balaban et al., 2005).
Initial observations suggest that up to 5% of the total molecular oxygen utilized by
mammalian mitochondria was converted into ROS (Boveris and Chance, 1973), but more
recent analysis estimates that about 1-2% was converted into O2.- anion (Cadenas and
Davies, 2000). Superoxide and other oxygen-derived reactive species (Brand et al.,
2004) directly or indirectly can damage proteins, lipids and DNA. To prevent ROSinduced injury, cells are equipped with an elaborate repertoire of antioxidant defense
systems (Halliwell and Gutteridge, 2007). There are three major primary intracellular
antioxidant enzymes in mammalian cells that can remove ROS: superoxide dismutase
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(SOD), catalase (CAT), and peroxidase, of which glutathione peroxidase (GPx) (Oberley,
2001) and peroxiredoxin (Prx) (Halliwell and Gutteridge, 2007) are the most prominent.
The SODs catalyze the dismutation of O2.- into hydrogen peroxide (H2O2) and molecular
oxygen.

Hydrogen peroxide is further detoxified by CAT, GPx (Halliwell and

Gutteridge, 1989) and Prx to water. Thus, two reactive species--O2.- and H2O2--are
converted to water (Oberley, 2001) and molecular oxygen. Any disturbance in the prooxidant and anti-oxidant balance in favor of the former is defined as oxidative stress
(Sies, 1985).
Among the antioxidant systems, SOD is considered the first line of defense
against oxidative stress (Halliwell, 1999; Ho et al., 1998). Four distinct SODs are found
in human cells: a homodimeric cytosolic copper zinc SOD (CuZnSOD) (McCord and
Fridovich, 1969), an mitochondrial inter-membrane space CuZnSOD (Okado-Matsumoto
and Fridovich, 2001), an extra-cellular homotetrameric glycosylated CuZnSOD
(Marklund, 1982) and a mitochondrial matrix homotetrameric manganese SOD
(MnSOD) (Weisiger and Fridovich, 1973). MnSOD is a critical antioxidant enzyme in
aerobic organisms because under physiological conditions superoxide is mainly
generated on the matrix side of the inner mitochondrial membrane where MnSOD is
located (Balzan et al., 1999). MnSOD is a homotetramer with identical 24-kd subunits
and one manganese ion per subunit (Matsuda et al., 1990). The mature protein is strictly
a mitochondrial enzyme compartmentalized in the mitochondrial matrix, although it is
encoded by the nuclear sod2 gene. Studies performed by us and others have shown that
an imbalance between antioxidants and oxidants leads to various pathological conditions
which can be effectively prevented or alleviated by increased MnSOD (Keller et al.,
1998; St Clair et al., 1991; Yen et al., 1996). The over-all importance of this enzyme is
evident from transgenic animal studies, wherein the MnSOD knock-out mice usually died
within 10 days after birth with cardiac abnormalities, fat accumulation in liver and
skeletal muscle (Lebovitz et al., 1996; Li et al., 1995) and metabolic acidosis (Lebovitz et
al., 1996); and the animals that survived longer than 10 days soon succumbed to severe
anemia and neurodegeneration (Melov et al., 1998).

It has been demonstrated that

MnSOD heterozygous knock-out mice show altered mitochondrial function, as illustrated
by decreased respiration by complex I and
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increased

sensitivity of

permeability

transition pore induction (Van Remmen et al., 2001), while overexpression of MnSOD
protects complex I from inactivation (Yen et al., 1999). Thus, it is likely that MnSOD
function influences mitochondrial function and oxidative phosphorylation, necessary
machinery for the production of ATP in cells.
MnSOD activity can be compromised by a post-translation modification, such as
nitration of tyrosine residues in its subunits (Ischiropoulos et al., 1992). Of the nine
tyrosine residues in each subunit of the homotetrameric MnSOD protein, tyrosine
residues 34, 45 and 193 have been shown to be nitrated, with nitration of tyrosine residue
34 causing inactivation of MnSOD (MacMillan-Crow et al., 1998).

Nitration of

biological macromolecules can be mediated by nitric oxide, nitrogen dioxide, nitrous
acid, hypochlorous acid, nitrated aliphatic reactive intermediates and peroxynitrite
(Ischiropoulos, 1998). Peroxynitrite has been demonstrated to nitrate tyrosine 34 of
MnSOD which leads to its inactivation (MacMillan-Crow et al., 1998; Yamakura et al.,
1998). Extensive data implicate peroxynitrite (ONOO-) as a consistent mediator of 3-NT
formation (MacMillan-Crow et al., 1996; Smith et al., 1996; Yamakura et al., 1998;
Yamamoto et al., 2002). Peroxynitrite is a powerful oxidant and cytotoxic agent formed
by the reaction between the free radicals nitric oxide (NO) and superoxide (O2.-) at rates
approaching diffusion limit (Beckman, 1996; Huie and Padmaja, 1993). The half life of
peroxynitrite is < 1s, and the homolytic cleavage results in the production of hydroxyl
radicals which have a much more deleterious effect than peroxynitrite itself (Beckman,
1996). Peroxynitrite causes oxidative damage to lipids, DNA, carbohydrates, proteins
and amino acids, such as cysteine, methionine, phenylalanine and tyrosine (Beckman and
Koppenol, 1996; Ischiropoulos and al-Mehdi, 1995). Externally added ONOO- has been
shown to diffuse passively across lipid bilayers (Denicola et al., 1998) over distances of
1 - 10 μm (Radi, 1998) with a permeability coefficient comparable to water (Marla et al.,
1997). Although one of the major oxidative modifications of proteins resulting from
peroxynitrite is carbonyl formation from side-chain and peptide-bond cleavage, perhaps
the best known property of ONOO- is its ability to nitrate free tyrosine and tyrosine
residues in proteins (Ischiropoulos et al., 1992; Souza et al., 1999).

It has been

demonstrated that ONOO- nitrates and inactivates MnSOD in chronic rejection human
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renal allograft, which has been proposed to be a general mechanism for amplification of
ONOO- induced damage (MacMillan-Crow et al., 1996). In addition to nitration of
MnSOD, ONOO- has also been shown to mediate inactivation of electron transport chain
components and ATPase, thereby inhibiting electron transport and ATP synthesis (Radi
et al., 1994) and increasing the rate of glycolysis (Bolanos et al., 1995). However, it is
unclear whether nitration of MnSOD is directly relevant to the observed peroxynitriteinduced alteration in energy production.
Bringing together the findings that MnSOD is sensitive to ONOO-, the role of
MnSOD in maintaining mitochondrial function and the contribution of mitochondrial
function to ATP production, we propose that nitrative inactivation of MnSOD is an
important event in peroxynitrite-induced alteration in metabolism. Here, we demonstrate
that exposure of human dopaminergic neuron SH-SY5Y cells to peroxynitrite (ONOO-)
leads to nitration and reduced activity of MnSOD. This is accompanied by decreased
mitochondrial function and complex I activity, and increased lactate levels, with no
decrease in ATP levels. The loss of mitochondrial function and complex I activity and
increase in lactate levels are alleviated by the presence of SOD mimetic. These results
suggest a novel role of MnSOD in mediating control of mitochondrial function and
energy production.
MATERIALS AND METHODS
Materials
Peroxynitrite was generously provided by Dr. Timothy R. Miller, University of
Texas at El Paso. All chemicals and reagents were purchased from Sigma-Aldrich (St.
Louis, MO) with the exception of the following: Nitro blue tetrazolium (NBT) was
purchased from Fisher Bioreagents (Fairlawn, NJ); protease inhibitor set III from
Calbiochem (La Jolla, CA); rabbit poly-clonal anti-nitrotyrosine from Cayman chemical
(Ann Arbor, MI); rabbit poly-clonal anti-MnSOD from Upstate Technology (Lake Placid,
NY); protein A/G agarose from Santa Cruz Biotechnology (Santa Cruz, CA); minimum
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essential medium (MEM) from GIBCO (Grand Island, NY); and standard fetal bovine
serum from Hyclone (Logan, UT). SOD mimetic (MnIIITE-2-PyP5+) was prepared as
previously described (Batinic-Haberle, 1999).
Cell Culture
SH-SY5Y, a human neuroblastoma cell line, was grown in MEM, supplemented
with 10% fetal bovine serum, 1% antibiotics (penicillin / streptomycin / neomycin), 1%
nonessential amino acids and 1 mM sodium pyruvate. Cells were cultured at 370C in a
humidified incubator with 5% CO2.
Animals
Heterozygous C57BL6 MnSOD knock-out mice (sod 2

+/-

) were originally

obtained from Dr. Charles J. Epstein, University of California at San Francisco, and
maintained as previously described (Van Remmen et al., 1999). The wild-type C57BL6
mice used for generation of sod 2 +/- mice were purchased from Harlan (Indianapolis, IN).
Characterization of MnSOD knock-out mice has been previously reported (Van Remmen
et al., 1999). A 30 – 80% decrease in MnSOD activity in all tissues (liver, kidney, lung,
brain, heart, muscle, stomach and spleen) of the heterozygous offspring has been
documented and no alterations in CuZnSOD, glutathione peroxidase or catalase activities
were found.

All mice used in the experiments were euthanized by intraperitoneal

injection with 68 mg/kg of Nembutal followed by cervical dislocation. The experimental
procedures were approved by the Institutional Animal Care and Use Committee of the
University of Kentucky.
Isolation of mitochondria
Three brains (excluding cerebellum) from each group were removed immediately
after animals were euthanized and were homogenized in 5 ml of ice-cold mitochondrial
buffer, pH 7.2, containing 0.225 mol/L D-mannitol, 0.075 mol/L sucrose, 20 mmol/L
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HEPES, 1 mmol/L EGTA and 1% bovine serum albumin in a Dounce homogenizer with
a Teflon pestle. The homogenized brain samples were then diluted with isolation buffer
to a final volume of 10 ml and centrifuged at 4500 rpm for 5 minutes. The supernatant
was transferred to a fresh tube on ice; the pellets were resuspended in isolation buffer,
and homogenized and centrifuged at 4500 rpm for 5 minutes. The supernatants were
combined and centrifuged at 10,000 rpm for 20 minutes. The brown mitochondrial
pellets were resuspended in 200 μl of respiration buffer or phosphate buffered saline, as
required.

Protein concentration was assessed by Bradford assay.

The isolated

mitochondria were used for immunoprecipitation of nitrated MnSOD, assessment of
oxygen consumption and activity of MnSOD.
Immunoprecipitation of Nitrated MnSOD
Isolated mitochondrial protein from the mouse brain or SH-SY5Y cell lysate (300
μg) was resuspended in 200 μl of RIPA buffer (10 mM TRIS, 150 mM NaCl, 1% sodium
deoxycholate, 1% Triton X-100 and 0.1% SDS, pH 7.5). Rabbit polyclonal nitrotyrosine
antibody (3 μg/ml) was added and incubated overnight at 40C. Protein A/G agarose
beads were added to the mixture and incubated overnight at 40C. Immunocomplexes
were collected by centrifugation at 12,000 rpm for 5 minutes at 40C, followed by washing
the complexes with RIPA buffer three times. The immunoprecipitated complexes were
resuspended in 2X sample buffer, boiled for 5 minutes, fractionated by reducing
SDS/polyacrylamide gel electrophoresis (PAGE) and analyzed by Western blot using
rabbit polyclonal MnSOD antibody.
Assessment of ATP
SH-SY5Y cells were plated at a density of 3 x 105 cells/well and treated with
indicated concentrations of peroxynitrite for 24 hours. The cells were collected in 1X
phosphate buffered saline (PBS) after washing twice with 1X PBS. The cells were lysed
by three freeze-thaw cycles. The cell lysate was used to assess the ATP level, using the
kit developed by Molecular probes (Invitrogen, Eugene, OR) according to the
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manufacturer’s instructions, and analyzed by T20/20 luminometer.

The tests were

repeated three times in triplicate.
Measurement of Glucose
Cell lysate prepared as described above for assessment of ATP was used to
determine glucose concentration using the Amplex Red glucose/glucose oxidase assay kit
developed by Molecular probes (Invitrogen, Eugene, OR) as per the manufacturer’s
instructions. The analysis was performed three times in triplicate.
Determination of Lactate level
Brains (excluding cerebellum) from MnSOD hetezygous knock-out (sod 2

+/-

)

mice were collected and washed twice in ice-cold PBS, and homogenized in Dounce
homogenizer using Teflon pestle. The homogenate was centrifuged at 5000 rpm for 5
minutes and the supernatant was used to determine the concentration of lactate. The SHSY5Y cell lysate, as described for assessment of ATP, was used to estimate the lactate
level. The reaction mixture contained 2M Tris; pH 7.5 in water with 0.05% sodium
azide, stored at room temperature; 60 mM NAD+ in water, stored at -200C; 15 mM INT,
prepared in water containing 10% (v/v) acetone; 100 units/ml Dase in 75 mM Tris; pH
7.5 stored at -200C; and 50 units/ml of lactate dehydrogenase (LDH). Just prior to the
beginning of the assay, Dase was diluted 1:100 with 75 mM Tris, pH 7.5. For the assay,
50 μl of the reaction reagent was added to 20 μl of the cell lysate in a 96-well flat bottom
microtitre plate. The reaction was allowed to continue for 40 minutes in a humidified
incubator without CO2. The reaction was stopped by adding 50 μl of 3% acetic acid,
followed by a brief agitation. The absorbance was measured at 492 nm using a Spectra
Max Gemini plate reader from Molecular Devices.

The reaction is based on the

production of NADH and pyruvate from NAD and lactate by LDH. This reaction is
coupled to Dase-catalyzed reoxidation of NADH to NAD and reduction of INT to red
colored formazan which is read at 492 nm. The intensity of the red color is proportional
to the concentration of lactate in the sample.
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Activity of Lactate Dehydrogenase
Lactate dehydrogenase (LDH) activity was assayed in the cell lysate of SH-SY5Y
cells treated with 250 μM peroxynitrite for 24 hours. The cells were washed twice with
1X PBS, collected in 1X PBS and homogenized using a hand homogenizer for 30
seconds. This was repeated three times with 30 second intervals. The homogenized cell
lysate was used immediately to determine LDH activity, following the method described
by Yen et al. (Yen et al., 1996).

Briefly, the cell lysate was added to a solution

containing NADH and incubated at room temperature for 20 minutes. Sodium pyruvate
(22.7 mM) in 0.1 M potassium phosphate buffer (pH 7.5) was added after 20 minutes. In
the assay, the reaction where pyruvate is converted to lactate catalyzed by LDH is
followed for two minutes.

The decrease in absorbance (dA/min – change in

absorbance/minute) at 340 nm that occurs with the oxidation of NADH to NAD is used
for calculating the LDH activity using the extinction coefficient of 6.22 mM-1cm-1 for
NADH. The activity was measured in three independent experiments, each in triplicate.
Activity of Pyruvate Dehydrogenase
The assay is based on the linking of the NADH produced by PDH to reduction of
the dye INT and was performed as described by Elnageh & Gaitonde (Elnageh and
Gaitonde, 1988). Briefly, the final reaction mixture of 1 ml volume consisted of 50 mM
Tris-HCL, 0.5 mM EDTA and 0.2% (wt/vol) Triton X-100 (pH 7.8), 20 μL of the cell
lysate, 2.5 mM NAD, 0.1 mM CoA, 1 mM MgCl2, 0.1 mM oxalate, 1 mg of bovine
serum albumin, 0.6 mM INT, 5-7 units of lipoamide dehydrogenase, 0.2 mM TPP and 5
mM pyruvate. After the addition of 4 mM TPP the contents were kept at 370C for 5
minutes. A stable baseline at 500 nm was obtained for the reaction mixture. The reaction
was started by adding 100 mM pyruvate. The absorbance of the mixture at 500 nm was
recorded at the beginning and again after the reaction had been underway for 5 minutes at
370C. Data was obtained from three independent experiments with triplicate samples.
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MTT Assay
The conversion of MTT dye to formazan dye crystals has been demonstrated to be
related to mitochondrial respiratory chain function (Musser and Oseroff, 1994). Cells
were plated at a concentration of 2 x 104 cells/well and treated with the indicated
concentrations of peroxynitrite or SOD mimetic (1000 pg/ml). MTT (1 mg/ml) was
added to the cell cultures and incubated for 45 minutes. Cells were then washed three
times with PBS, solubilized in dimethylsulfoxide, and the absorbance was quantified at
540 nm using a Spectra Max Gemini plate reader from Molecular Devices. The data was
obtained from three independent experiments with six replications each.
Activity of Complex I
Brains (excluding cerebellum) from sod 2

+/-

mice were collected and washed

twice in ice-cold PBS, and homogenized in Dounce homogenizer using Teflon pestle.
The homogenate was used to estimate the activity of complex I. SH-SY5Y cells treated
-

with 250 μM of ONOO for 24 hours were washed twice in 1X PBS, collected in
hypotonic buffer (20 mM potassium buffer, pH 7.2) and lysed by three cycles of fast
freeze-thaw. The specific activity of complex I was assayed as described previously
(Lash and Jones, 1993), with slight modifications. Briefly, the assay mixture containing
25 mM of potassium phosphate buffer (pH 7.2), 5 mM MgCl2, 2 mM KCN, 2.5 mg/ml
bovine serum albumin (fraction V), 0.13 mM NADH, 65 μM coenzyme Q5 and 2 μg/ml
antimycin A were incubated at 300C for 1 minute. The cell lysate/brain homogenate was
added to initiate the reaction and the initial rate of NADH oxidation was monitored at
340 nm (ε 6.81 mM-1 cm-1) for 1 minute. The complex I specific activity was inhibited
by 2 μg/ml of rotenone. Complex I activity was calculated by the differences in dA/min
with and without rotenone.

Activity was determined from three independent

experiments, in triplicate, for cells and from three mice.
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Activity of MnSOD
SOD activity in the isolated mitochondria from brains of wild-type (WT) mice or
from SH-SY5Y cell lysate was measured by the nitro blue tetrazolium (NBT)bathocuprione sulfonate reduction inhibition method (Spitz and Oberley, 1989). This
assay is based on the competitive reaction between SOD and the indicator molecule NBT
for superoxide radicals generated by xanthine/xanthine oxidase. The reduction of NBT is
progressively inhibited in relation to addition of protein (containing SOD activity).
Because potassium cyanide (5 mmol/L) was used to inhibit Cu/ZnSOD, this method
measured only MnSOD activity. The assay mixture also contained catalase to remove
H2O2 and diethylenetriaminepentaacetic acid to chelate metal ions capable of redox
cycling and interfering with the assay system. The reduction of NBT to blue formazan by
superoxide with/without cell lysate or isolated brain mitochondria was measured
spectrophotometrically at 560 nm at 250C. The rate of NBT reduction in the absence of
cell lysate or isolated brain mitochondria was used as the reference rate (0.02 ± 0.005
absorbance/min). The data were plotted as percent of inhibition of NBT reduction versus
protein concentration. One unit of SOD activity was defined as the amount of SOD
protein that caused a 50% reduction in the background rate of NBT reduction. The
activity of MnSOD was determined in triplicate from three independent experiments.
Mitochondrial Respiration Assay
Mitochondrial protein (400 μg) was resuspended in the respiration buffer
containing 0.25 mol/L sucrose, 50 mmol/L HEPES, 2 mmol/L MgCl2, 1 mmol/L EGTA,
10 mmol/L KH2PO4 and 0.5% bovine serum albumin, pH 7.4. Oxygen consumption was
measured using a Clark-type electrode oxygraph (Hansatech Inc., Norfolk, UK) with 10
mmol/L pyruvate and 5 mmol/L malate as substrate in the absence of ADP (state II
respiration), and after addition of 300 mmol/L ADP (state III respiration). The ATPase
inhibitor oligomycin (100 μg/ml) was then added to inhibit mitochondrial respiration
(state IV respiration). The ratio between the rate of oxygen consumption/min of state III
and state IV was used to calculate the respiratory control ratio (RCR).
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RNA Interference
siRNA (Thermoscientific Dharmacon, On-TARGETplus SMARTpool) was used
to selectively knock-down MnSOD. SH-SY5Y cells were plated at 40% confluence at
the time of transfection and transfected with control siRNA or MnSOD siRNA using
oligofectamine for 12 hours in a serum-reduced Opti-MEM (Invitrogen). The cells were
washed with 1X PBS 48 hours after transfection and lysed by incubating for 30 minutes
with lysis buffer (25 mM Tris-phosphate, pH 7.8, 2 mM dithiothretol, 2 mM 1, 2 –
diaminocyclohexane N, N, N’, N’ – tetraacetic acid, 10% glycerol and 1% Triton X-100).
Suppression of MnSOD was analyzed by Western blot. Briefly, equal amounts of cell
lysate proteins were resuspended in 2X sample loading buffer and SDS-PAGE was
performed on 12.5% polyacrylamide gels. Proteins were transferred electrophoretically
(100V, 1 hour) to nitrocellulose membranes (Schleicher & Schuell, Dassell, Germany).
Membranes were blocked using 5% nonfat dried milk in 50 mmol/L Tris, pH 7.9, 150
mmol/L NaCl, and 0.05% (v/v) Tween-20. For detection of MnSOD, nitrocellulose
membranes were incubated overnight at 40C with polyclonal MnSOD antibody at a
dilution of 1:10000. This was followed by incubation with horseradish peroxidaseconjugated anti-rabbit secondary antibody. Probed membranes were washed three times,
and immunoreactive proteins were detected using enhanced chemiluminescence
(Amersham Corp., Piscataway, NJ). Western blot analysis was conducted three times;
the representative blot is shown in the manuscript.
Statistical analysis
Data were evaluated using either analysis of variance (ANOVA) with post-hoc
Tukey’s multiple comparison test or Student’s t-test. A difference of p < 0.05 was
considered significant.
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RESULTS
Peroxynitrite induced nitration and inactivation of MnSOD in SH-SY5Y cells
It has been shown that MnSOD is nitrated at tyrosine residue 34 and subsequently
inactivated by peroxynitrite (Yamakura et al., 1998).

The experimental model used in

this study demonstrates nitrated MnSOD and is the first step toward establishing a cell
culture model for investigating the effect of MnSOD inactivation on cellular metabolism.
SH-SY5Y were treated with 250 μM peroxynitrite and incubated for 24 hours. The
presence of nitrated MnSOD was identified by immunoprecipitation using a polyclonal
nitrotyrosine

antibody

followed

by

Western

analysis

of

MnSOD

protein.

Immunodetection with polyclonal MnSOD antibody demonstrated an appreciable amount
of nitrated MnSOD in cells treated with peroxynitrite (Figure 3.1A).
To verify that the presence of nitrotyrosine in MnSOD is associated with reduced
MnSOD activity, we measured MnSOD activity in cells treated with 250 μM
peroxynitrite. MnSOD activity in peroxynitrite treated cells was significantly reduced
compared to control (Figure 3.1B).
Alteration in mitochondrial function in SH-SY5Y cells is associated with MnSOD
activity
To determine whether the decreased activity of MnSOD is associated with
decreased mitochondrial function, we performed MTT assay (a measurement of
mitochondrial dehydrogenase function) in SH-SY5Y cells 24 hours after treatment with
250 μM peroxynitrite. Quantification of absorbance of the solubilized formazan at 540
nm revealed a significant reduction (p < 0.001) (Figure 3.2A) in the MTT level in cells
treated with peroxynitrite.
We have previously demonstrated that overexpression of MnSOD protects
complex I from Adriamycin induced inactivation (Yen et al., 1999). To determine
whether the observed decrease in MnSOD activity in peroxynitrite treated cells has any
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Figure 3.1 Treatment with peroxynitrite induces nitration and reduced activity of
MnSOD in SH-SY5Y cells
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Figure 3.1 Treatment with peroxynitrite induces nitration and reduced activity of
MnSOD in SH-SY5Y cells.
A. Immunoprecipitation (IP) of MnSOD tyrosine nitration. SH-SY5Y cell lysate was
precipitated with nitrotyrosine antibody and analyzed by Western blot using MnSOD
antibody. Positive control – Isolated brain mitochondria treated with 250 μM
peroxynitrite, Negative control – Isolated brain mitochondria precipitated with nonimmune rabbit IgG and analyzed by Western blotting using MnSOD antibody. PEL –
pellet, SUP – supernatant.
B. MnSOD activity in SH-SY5Y cells treated with 250 μM peroxynitrite was measured by
NBT-bathocuprione sulfonate reduction inhibition method. The activity was measured
in triplicate at 24 hours post treatment in three sets of independent experiments. *, p <
0.05, compared with the control.
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effect on the activity of complex I, we assessed the activity of complex I in SH-SY5Y
cells treated with 250 μM peroxynitrite and incubated for 24 hours. As shown in Figure
3.2B, the activity of complex I was significantly reduced (p < 0.05) in comparison with
the untreated control.
SOD

mimetic

(MnIIITE-2-PyP5+)

protects

against

peroxynitrite–induced

mitochondrial dysfunction
Although the reduced MnSOD activity and concurrent reduction in mitochondrial
function and complex I activity are interrelated, the interrelationship does not
demonstrate that reduction of MnSOD activity is a cause for reduced mitochondrial
function. To further establish the role of MnSOD on mitochondrial function, we pretreated the SH-SY5Y cells for 24 hours with SOD mimetic and measured mitochondrial
function after treatment with peroxynitrite. Cells were pre-treated with SOD mimetic
(1000 pg/ml) for 24 hours and then exposed to 250 μM peroxynitrite. The results show
that the loss of complex I activity was reduced in the cells with SOD mimetic pretreatment (p < 0.05) (Figure 3.3A).
To verify further that MnSOD indeed contributes to mitochondrial function, we
used the siRNA approach. SH-SY5Y cells were transfected with control siRNA or
MnSOD siRNA using oligofectamine. Cells were harvested 48 hours after transfection
and expression of MnSOD was verified by Western blot.

There was a substantial

suppression of MnSOD level (Figure 3.3B) in the cells transfected with MnSOD siRNA.
These transfected cells were used for determination of complex I activity. The cells
transfected with MnSOD siRNA showed significant decrease (p < 0.05) in complex I
activity in comparison with untransfected control (Figure 3.3C).
MnSOD activity is sensitive to peroxynitrite induced inactivation
The results demonstrated in Figure 3.2 suggest that reduced activity of MnSOD
may contribute to the loss of mitochondrial function. They do not indicate, however,
whether MnSOD activity or mitochondrial function is more sensitive to peroxynitrite67
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Figure 3.2 Peroxynitrite reduces mitochondrial complex I activity and mitochondrial
function in SH-SY5Y cells.
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Figure 3.2 Peroxynitrite reduces mitochondrial complex I activity and mitochondrial
function in SH-SY5Y cells.
A. Mitochondrial function was assessed by the ability of the mitochondria to uptake and
reduce MTT, 24 hours after SH-SY5Y cells were treated with 250 μM peroxynitrite.
B. Complex I activity in SH-SY5Y cells treated with 250 μM peroxynitrite in the same
manner described in A. All measurements were performed in triplicate. The data are
averages from three sets of independent experiments. **, p < 0.01, *, p < 0.05,
compared with the control.
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Figure 3.3

SOD mimetic and MnSOD siRNA alter mitochondrial complex I
activity.
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Figure 3.3 SOD mimetic and MnSOD siRNA alter mitochondrial complex I activity.
A. SH-SY5Y cells were treated with SOD mimetic (1000 pg/ml) for 24 hours, followed by
treatment with 250 μM peroxynitrite for an additional 24 hours.
B. Western blot using polyclonal MnSOD and GAPDH antibody, csiRNA – control
siRNA, siRNA – MnSOD siRNA.
C. Complex I activity (nmoles/min/mg protein) in SH-SY5Y cells transfected with
MnSOD siRNA. The measurements were performed in triplicate. All data represent
the average of three independent experimental sets. *, p < 0.05, #, p < 0.05, compared
with the control and 250 μM ONOO respectively.
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induced inactivation. To answer this question, we conducted a dose-response experiment
in mitochondria isolated from mouse brain. The isolated mitochondria were treated with
0, 1, 10, 100 or 250 μM peroxynitrite for 1 minute and then oxygen consumption was
measured as an indicator of mitochondrial respiration chain activity using a Clark-type
electrode oxygraph with pyruvate and malate as substrates in the absence of ADP (state II
respiration), or presence of ADP (state III respiration). The ATPase inhibitor oligomycin
was then added to inhibit mitochondrial respiration (state IV respiration). The RCR was
not affected and was comparable to the untreated control when exposed to 1 μM
peroxynitrite, whereas the RCR was significantly decreased (p < 0.001) at all other
concentrations of peroxynitrite (Figure 3.4A).

The data obtained from respiration

analysis show that 1 μM did not affect the RCR, whereas the activity of MnSOD was
significantly reduced (p < 0.01) at this concentration (Figure 3.4B). This result indicates
that MnSOD is inactivated by peroxynitrite at concentrations lower than what is required
to observe the loss of mitochondrial respiration function.
Concomitant with the reduced activity of MnSOD, immunoprecipitation
performed on the mitochondria treated with 1 μM and 10 μM peroxynitrite demonstrated
appreciable levels of nitrated MnSOD (Figure 3.4C). This indicates that the observed
reduced activity of MnSOD treated with 1 μM is associated with peroxynitrite-induced
nitration of MnSOD.
Peroxynitrite has no effect on cellular ATP levels
Because treatment with peroxynitrite resulted in a reduction in mitochondrial
respiration capacity, we explored the impact of this change on cellular ATP levels. Cells
were treated with 250 μM peroxynitrite and the total cellular levels of ATP were
compared 24 hours after treatment

(Figure 3.5). The level of ATP in peroxynitrite

treated cells was comparable to that of control cells.

The cells treated with 2

deoxyglucose (2DG), a glycolytic inhibitor used as a positive control, showed significant
decrease (p < 0.001) in ATP levels in comparison with both untreated cells and
peroxynitrite treated cells (Figure 3.5).
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Figure 3.4 MnSOD activity is more sensitive to peroxynitrite than mitochondrial
respiration.
A. RCR of isolated mitochondria protein from mouse brain tissues. RCR was calculated
as the ratio between state 3 and state 4 respirations. Mitochondria were exposed to the
indicated concentrations of peroxynitrite for 1 minute prior to the oxygen consumption
measurement.
B. MnSOD activity was measured from isolated mitochondrial protein treated with
indicated concentrations of peroxynitrite for 1 minute.
C. Nitrotyrosine containing mitochondrial protein was precipitated with nitrotyrosine
antibody and analyzed by Western blot using MnSOD antibody. Positive control –
Isolated brain mitochondria treated with 250 μM peroxynitrite, Negative control Isolated brain mitochondria precipitated with non-immune rabbit IgG and analyzed by
Western blotting using MnSOD antibody. PEL – pellet, SUP – supernatant. All
measurements were performed in triplicate. The data shown is the average of three
experimental sets. ***, p < 0.001, **, p < 0.01, compared with the control.
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ATP level

Figure 3.5 Peroxynitrite treatment does not alter ATP levels in SH-SY5Y cells. ATP
was measured in SH-SY5Y cells treated with 250 μM peroxynitrite or 5.5 mM 2DG for 24
hours. 2DG was used as positive control. The measurements were performed in triplicate.
The data represent an average from three sets of independent experiments. ***, p < 0.001,
compared with the control.
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Peroxynitrite mediated increase in glycolytic activity
Because the total cellular ATP was maintained in cells with reduced respiratory
function, it is possible that glycolysis may compensate for the production of ATP. To
address this question, we measured the concentration of lactate 24 hours after treating the
SH-SY5Y cells with 250 μM peroxynitrite. The concentration of lactate in cell lysate
treated with peroxynitrite was significantly increased (p < 0.01) in comparison with the
untreated controls (Figure 3.6A). The activity of lactate dehydrogenase, an enzyme that
catalyzes the conversion of pyruvate to lactate, was also significantly increased (p <
0.001) in the cell lysates treated with 250 μM peroxynitrite (Figure 3.6B). These results
indicate that glycolytic activity increases in peroxynitrite treated cells.
The increase in glycolytic activity suggests that peroxynitrite treated cells may
have a higher level of glucose, which was assessed by the glucose concentrations in the
cell lysate. The results indicate that the concentration of glucose was significantly higher
(p < 0.05) in peroxynitrite treated cells in comparison with control cells (Figure 3.7A).
Pyruvate dehydrogenase (PDH) catalyzes the conversion of pyruvate to AcetylCoA, which then enters the tri-carboxylic cycle. Decreased activity of PDH would lead
to accumulation of pyruvate, which can be converted to lactate by lactate dehydrogenase.
To probe this possibility, we analyzed the activity of PDH in SH-SY5Y cells 24 hours
after treatment with 250 μM peroxynitrite. The results show that the activity of PDH was
significantly decreased (p < 0.001) in peroxynitrite treated cells in comparison with the
untreated control (Figure 3.7B).
Suppression of MnSOD enhances glycolytic activity
The increase in glycolytic activity obtained in cells treated with peroxynitrite
suggests that MnSOD has a role in this process. To test this possibility, we reduced the
MnSOD level by transfecting SH-SY5Y cells with control siRNA or MnSOD siRNA.
The cells were harvested 48 hours after transfection and suppression of MnSOD was
confirmed by Western analysis (data not shown). The corresponding cell lysates were
used for measurement of lactate concentration and LDH activity.
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Figure 3.6 Peroxynitrite increases the levels of lactate and activity of lactate
dehydrogenase in SH-SY5Y cells.
A. Concentrations of lactate.
B. Activity of LDH.
All these measurements were performed in triplicate. The data are the average of three
experimental sets. **, p < 0.01, compared with the control.
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Figure 3.7 Peroxynitrite increases the levels of glucose and suppresses the activity of
pyruvate dehydrogenase in SH-SY5Y cells.
A. Concentrations of glucose.
B. Activities of PDH.
All these measurements were performed in triplicate. The data are the average of three
experimental sets. *, p < 0.05, **, p < 0.01, compared with the control.
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concentration (p < 0.01) and LDH activity (p < 0.05) were significantly increased in cells
transfected with MnSOD siRNA (Figure 3.8A and B). This increase in lactate levels
suggests that increased glycolytic activity compensates for reduced respiration due to
reduction of MnSOD activity.
To test this possibility we investigated whether the compensatory increase in
glycolytic activity is altered by the presence of SOD mimetic. SH-SY5Y cells were pretreated for 24 hours with SOD mimetic (1000 pg/ml) followed by treatment with 250 μM
peroxynitrite. Lactate levels were significantly higher (p < 0.05) in the group treated with
peroxynitrite alone. However, in the SOD mimetic pre-treated group, lactate levels were
comparable to those of the control cells and were significantly less (p < 0.05) in
comparison with the peroxynitrite treated group (Figure 3.9A). This indicates that SOD
mimetic protects the mitochondrial function and, thus, there is no compensatory increase
in glycolytic activity. The cells treated with mimetic showed significantly increased
activity of pyruvate dehydrogenase (p < 0.01) in comparison with the group treated with
peroxynitrite (Figure 3.9B).
Decreased mitochondrial respiration and increased glycolytic activity in sod 2

+/-

mice
All the above observations made in-vitro suggest that reduction in MnSOD
activity is associated with mitochondrial dysfunction and increase in glycolytic activity.
To verify that this phenomenon is occurring in-vivo, we used sod 2
activity in sod 2

+/-

+/-

mice.

MnSOD

mice has been shown to be decreased (30 – 80%) in all tissues

examined in comparison with sod 2
from both sod 2

+/-

+/+

mice (Van Remmen et al., 1999). Three mice

and WT mice were euthanized. Brains (excluding cerebellum) were

collected and used for analysis of mitochondrial respiration, complex I activity and
lactate concentration. The results show that the RCR of sod 2 +/- mice mitochondria was
significantly reduced (p < 0.05) in comparison with WT mice (Figure 3.10A).
The activity of complex I in whole brain homogenate was significantly reduced (p
< 0.01) in comparison with WT mice (Figure 3.10B). The respiration and activity of
complex I indicate that the mitochondrial function in the brain of sod 2
79

+/-

mice was

compromised. To investigate whether glycolytic activity is increased to compensate for
this loss of mitochondrial function, the concentration of lactate was evaluated. The
concentration of lactate was significantly higher in sod 2
comparison with WT mice (Figure 3.10C).
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+/-

mice (p < 0.01) in

Lactate

A

LDH activity

B

Figure 3.8 Suppression of MnSOD enhances the levels of lactate and activity of
lactate dehydrogenase.
A. Concentration of lactate.
B. Activity of Lactate dehydrogenase. All measurements were performed in triplicate.
csiRNA – control siRNA, siRNA – MnSOD siRNA.
The data are the average of three experimental sets. *, p < 0.05, **, p < 0.01, compared
with the control and csi RNA respectively.
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Figure 3.9 SOD mimetic (MnIIITE-2-PyP5+) (1000 pg/ml) suppresses the level of lactate
and increases the activity of pyruvate dehydrogenase.
A. Concentration of lactate.
B. Activity of PDH. All estimates were done in triplicate.
The data are the average of three experimental sets. *, p < 0.05, **, p < 0.01, compared with
the control; #, $, p < 0.05, compared with the 250 μM ONOO.
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Figure 3.10 MnSOD deficiency leads to alteration in oxygen consumption,
complex 1 activity and levels of lactate.
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Figure 3.10 MnSOD deficiency leads to alteration in oxygen consumption, complex 1
activity and levels of lactate.
A. Mitochondrial respiration in isolated mitochondria protein from brains.
B. Complex I activity and lactate levels in whole brain homogenate of sod 2 +/- mice.
C. Levels of lactate in whole brain homogenate of sod 2 +/- mice.
All measurements were performed in triplicate from three animals. *, p < 0.05, **, p < 0.01,
compared with the WT.
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DISCUSSION
Manganese superoxide dismutase (MnSOD) is the only isoform of SOD found
inside the mitochondrial matrix of eukaryotic cells (Quijano et al., 2001) and its presence
is essential for the survival of aerobic life (Lebovitz et al., 1996; Li et al., 1995; Melov et
al., 1998). Mitochondria are major organelles where most of the cell superoxide is
produced. Thus, MnSOD plays a critical role in protecting the cell from superoxide
radicals (Fridovich, 1975).
Mitochondria are essential for the production of ATP through oxidative
phosphorylation, and it has been shown that peroxynitrite, a strong oxidant that is a
product of nitric oxide and superoxide, can nitrate tyrosine 34 of MnSOD, thereby
inactivating it (MacMillan-Crow et al., 1998). We therefore asked whether inactivation
of MnSOD by nitration influences the mode of energy production in mammalian cells.
We treated SH-SY5Y neuroblastoma cells with peroxynitrite to induce nitration and
subsequent inactivation of MnSOD. The results demonstrate that there is a link between
the shift in energy metabolism and nitrative inactivation of MnSOD in SH-SY5Y cells.
The data indicate that reduction of MnSOD activity leads to a reduction in mitochondrial
respiration and an increase in glycolytic activity.
Nitration of biological macromolecules can be caused by nitric oxide, nitrogen
dioxide, nitrous acid, hypochlorous acid, nitrated aliphatic reactive intermediates and
peroxynitrite (Ischiropoulos, 1998). But only peroxynitrite mediates the inactivation of
MnSOD by exclusive nitration of tyrosine residue 34. Tyrosine 34 is located at the
vertex of the substrate channel and only 5 Å from the active manganese ion site of
MnSOD (Yamakura et al., 1998). This makes this residue most susceptible to nitration
because peroxynitrite is attracted to the active site by the basic residues in the channel
entrance (Quijano et al., 2001) and the ionization state of tyrosine 34 is altered by
positively charged manganese atoms making it prone to an electrophilic attack
(MacMillan-Crow et al., 1998). Being a major player in removing superoxide, it is
possible that nitration and inactivation of MnSOD would result in an increase in
mitochondrial superoxide levels leading to enhanced generation of peroxynitrite, thereby
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amplifying

the

nitration/oxidation

of

mitochondrial

proteins

and

eventually

compromising mitochondrial function.
The involvement of MnSOD activity in the maintenance of mitochondrial
function has been amply documented by studies using sod 2 +/- mice that show a decrease
in mitochondrial function as measured by reduced RCR for the substrates of complex I
(Van Remmen et al., 2001). The data obtained from our study of cells treated with
peroxynitrite show that decreased activity of complex I is associated with nitration and
inactivation of MnSOD. Complex I function can be affected by either direct reaction of
superoxide radicals that might accumulate because of reduced MnSOD activity or by
direct inactivation of complex I by enhanced production of peroxynitrite (Cassina and
Radi, 1996; Rusak et al., 2006). Several lines of experiments indicate that MnSOD
activity is important for the protection of mitochondrial function and complex I activity.
First, the uptake and reduction of MTT, an indicator for mitochondrial function and
complex I activity (Musser and Oseroff, 1994), are reduced. Second, it has been shown
that overexpression of MnSOD selectively protects complex I inactivation in transgenic
mice treated with adriamycin (Yen et al., 1999) and in lung carcinoma cells exposed to
hypoxia-reoxygenation (Powell and Jackson, 2003). Importantly, our data demonstrate
that the loss in complex I activity in cells treated with peroxynitrite was alleviated by the
presence of a SOD mimetic (MnIIITE-2-PyP5+) capable of localizing in the mitochondria.
It should be noted that this result is confounded by the ability of SOD mimetic (MnIIITE2-PyP5+) to be a scavenger of peroxynitrite (Ferrer-Sueta et al., 2003; Spasojevic et al.,
2007) but reduced activity of complex I exhibited in SH-SY5Y cells transfected with
MnSOD siRNA is consistent with the role of MnSOD in protecting complex I activity.
Since complex I represents a point of entry of electrons from NADH-linked
substrates, loss of its activity probably will result in reduced electron flux to the
respiratory chain (Radi et al., 1994) and thereby mitochondrial function, and it therefore
follows that reduced activity of MnSOD (Van Remmen et al., 2001) and exposure to
peroxynitrite (Cassina and Radi, 1996) will result in compromised mitochondrial
function. Although there are multiple targets for peroxynitrite in mitochondria (Cassina
and Radi, 1996; MacMillan-Crow et al., 1998; Rusak et al., 2006; Yamakura et al., 1998),
our result demonstrates that MnSOD is an early target in the process of peroxynitrite86

induced mitochondrial dysfunction. MnSOD was inactivated at 1 µM peroxynitrite, but
respiration was inhibited at 10- fold higher concentrations. Given the transient nature of
peroxynitrite in biological systems, the early inactivation of MnSOD, an important antioxidant enzyme in the mitochondria, is of immense importance. MnSOD can inhibit
peroxynitrite formation in the mitochondria (Radi et al., 1994), but its inactivation can
possibly lead to an increase in intramitochondrial superoxide levels and additional
generation of peroxynitrite (MacMillan-Crow et al., 1996). This can propagate the initial
damaging event that leads to mitochondrial dysfunction (Radi et al., 1994). Further proof
of the involvement of MnSOD in protecting mitochondrial function is the decreased
activity of complex I and reduced RCR in sod 2 +/- mice. Our results are consistent with
the results from an earlier study showing a reduction of RCR and state III respiration in
mitochondria isolated from the heart of Sod 2

+/-

mice (Van Remmen et al., 2001) and

extend to demonstrate the effect of MnSOD in brain mitochondria. Together these data
demonstrate an important role for MnSOD in protecting the respiratory function of
mitochondria.
Mitochondrial respiration is the most important contributor to the cell’s energy
requirement, producing 32 ATPs from one glucose molecule. Thus, dysfunction of
respiratory complexes would eventually lead to compromised respiration and thereby loss
of ATP generation from oxidative phosphorylation. The ability of cells to shift from
oxidative phosphorylation to glycolysis has been observed in many tumors with impaired
mitochondrial function (Gatenby and Gillies, 2004).

Our data suggest that both

SH-SY5Y cells treated with peroxynitrite and brain tissue in MnSOD deficient mice were
capable of maintaining their required energy by up- regulating glycolytic activity. The
lactate levels in cells treated with peroxynitrite were increased in comparison with control
cells, suggesting increased glycolytic activity. These results are consistent with those
obtained from platelets (Rusak et al., 2006) and primary neuronal cells (Bolanos et al.,
1995) exhibiting decreased mitochondrial respiration when treated with peroxynitrite.
The conversion of pyruvate to lactate is catalyzed by the NADH-dependent enzyme,
lactate dehydrogenase (LDH). Compared with the untreated cells, peroxynitrite treated
cells exhibited a higher activity of lactate dehydrogenase which was similar to the
observed increased lactate levels. The activities of mitochondria and LDH are delicately
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and mutually regulated at the level of metabolites. They depend on the availability of
pyruvate and NADH/NAD+.

Pyruvate accumulates in the cell under conditions of

decreased activity of pyruvate dehydrogenase, which oxidizes pyruvate to acetyl-coA,
thereby facilitating the entry of pyruvate into kreb’s cycle. Consistent with this model,
we found reduced activity of PDH in cells treated with peroxynitrite. The fast kinetics of
LDH ensures that accumulated pyruvate is converted to lactate (Fantin et al., 2006).
Pyruvate to lactate conversion utilizes NADH and regenerates NAD+ which can be used
to drive glycolysis, which produces more lactate. As more and more NADH is consumed
for this reaction, less NADH is available for mitochondrial respiration, thereby slowing
down the already impaired respiration in cells treated with peroxynitrite. A high rate of
conversion of glucose to lactate is coupled to a high rate of glucose uptake and glucose
phosphorylation and occurs even in the presence of normal oxygen pressure (Gatenby
and Gillies, 2004). In this study, SH-SY5Y cells treated with peroxynitrite also showed
significantly increased levels of glucose.

Thus, it seems probable that impaired

mitochondrial function due to reduced MnSOD activity leads to a compensatory increase
in glycolysis. This possibility is further supported by the finding that cells transfected
with MnSOD siRNA have increased levels of lactate and lactate dehydrogenase activity.
Compensating for SOD activity with a SOD mimetic in the cells treated with
peroxynitrite resulted in reduction of lactate concentration and alleviation of PDH
activity. Our results from in-vivo experiments with sod 2+/- mice demonstrate increased
lactate levels in the brain. Those results further support the likelihood that alteration in
MnSOD activity plays a key role in reducing mitochondrial function and subsequently
compensating for the energy requirements of cells by the up- regulation of glycolytic
activity.
Increased nitrotyrosine has been documented in hippocampus and cerebral cortex
of aged rats (Shin et al., 2002), cerebrospinal fluid of aged humans (Tohgi et al., 1999)
and in many neurodegenerative disorders (Torreilles et al., 1999). The identities of many
proteins modified by nitration have been obtained in human, animal and cellular models
of diseases (Ara et al., 1998; Sultana et al., 2006). However, MnSOD was the first
protein unequivocally identified as nitrated in chronic rejection of human renal allografts
(MacMillan-Crow et al., 1996). A previous study from our lab has shown the presence of
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nitrated MnSOD in brains of APP/PS-1 double knock-in mouse model of Alzheimer’s
disease (Anantharaman et al., 2006).

To our knowledge, this is the first study to

implicate the inactivation of MnSOD to the metabolic switch occurring under conditions
of mitochondrial dysfunction.
In summary, we demonstrate that MnSOD was nitrated upon peroxynitrite
treatment with an associated decrease in activity. Inactivation of MnSOD is an early
event in peroxynitrite-induced impairment of mitochondrial function.

Mitochondrial

dysfunction was compensated for by an increase in glycolytic activity. Mitochondrial
dysfunction and increased glycolytic activity were prevented by SOD mimetic and
enhanced by MnSOD deficiency. These results demonstrate a critical role for MnSOD in
maintaining mitochondrial respiratory function and reveal the role of glycolysis in
sustaining cellular energy requirements under pathological conditions associated with
MnSOD deficiency.

Copyright © Muthuswamy Anantharman 2008
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CHAPTER FOUR
INCREASED GLYCOLYSIS IN THE APPNLh/NLh X PS-1P264L/P264L DOUBLE
KNOCK-IN MOUSE MODEL OF ALZHEIMER’S DISEASE
ABSTRACT
Altered energy metabolism is characteristic of many neurodegenerative disorders.
In AD patients, memory dysfunction is associated with glucose hypometabolism and
neuronal loss in the hippocampus. In addition to the role in the pathogenesis of AD, Aβ
peptide has been associated with reduced glucose oxidative metabolism and
mitochondrial activity. Here, brains from APPNLh/NLh X PS-1P264L/P264L Double Knock-In
Mouse Model of Alzheimer’s disease (APP/PS-1) were used to investigate a possible
change in glycolytic activity. We estimated the levels of lactate, the activity of lactate
dehydrogenase (LDH) and pyruvate dehydrogenase (PDH) from 3 and 14-16 months old
APP/PS-1 mice and wild-type (WT) mice. Significantly increased lactate levels were
observed in 14-16 months old APP/PS-1 mice when compared to their age-matched WT
counterparts. The activity of LDH was also significantly increased in the APP/PS-1
mice. PDH appears to have age associated decrease in activity and was significantly
decreased in APP/PS-1 mice when compared to age-matched WT mice. These findings
implicate a possibility of an increased glycolytic activity in APP/PS-1 mice.
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INTRODUCTION
Glucose is an essential energy source for the adult human brain. The brain is
metabolically the most active organ and is therefore highly dependent on a continuous
supply of its fuel. To meet its very high energy demands, the brain (around 1/40 of the
body weight) prossesses a relatively high blood flow and glucose consumption equal in
amount to about one-fifth of the entire resting requirements of the body (Roeder et al.,
1982). When the blood glucose levels fall by half from a normal fasting value (to about 2
– 3 mM), there is some cognitive impairment and, at glucose levels below 1 mM, mental
confusion is evident and coma may result from sustained glucose deprivation.
Modern humans acquired enhanced longevity accompanied by the expansion of
lifetime in nonreproductive ages. However, this prolonged lifetime brought up negative
assets: late-onset diseases such as AD. Reported characteristics of AD brain are impaired
energy metabolism, and increased oxidative stress (Fukui et al., 2007). Early impairment
of memory and learning are characteristic features of AD. These symptoms correspond
well to the glucose hypometabolism present even at early stages of the disease when only
mild cognitive impairment is evident clinically (de Leon et al., 2001; De Santi et al.,
2001).

Most of the evidence suggesting an impairment of cerebral energy metabolism

has come from in vivo studies as detected by reduced cortical [18F] deoxyglucose uptake
using positron emission tomography (Mielke et al., 1996). Accordingly, activities of key
glycolytic enzymes like hexokinase, aldolase, pyruvate kinase, lactate dehydrogenase and
glucose – 6 – phosphate dehydrogenase were found to be altered in AD patients (Bigl et
al., 1999) along with a reduction in densities of glucose transporter subtypes (GLUT1 and
GLUT 3) (Bigl et al., 2003). However, with respect to several other enzymes the results
have been contradictory.
Transgenic animals developed to model AD pathology by overexpression of
mutated form of APP and PS-1 also demonstrate decreased hippocampal glucose
metabolism with a positive correlation to the deposition of Aβ plaque (Sadowski et al.,
2004).

Here a APPNLh/NLh X PS-1P264L/P264L Double Knock-In Mouse Model of

Alzheimer’s Disease (APP/PS-1) carrying a Swedish familial AD mutation in amyloid
precursor protein and having the P264L familial AD mutation in presenilin – 1 (Chapter
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two) were used to investigate a possible change in glycolytic activity. This mouse has
been demonstrated to display increased Aβ deposition from 6 months onwards consistent
with an increase in the levels Aβ 1-40 and Aβ 1-42. The finding of increased glycolytic
activity in the event of decreased mitochondrial function in SH-SY5Y cells (Chapter
three) in association with decreased activity of MnSOD prompted us to investigate
whether APP/PS-1 mice with decreased mitochondrial function (Chapter two)
(Anantharaman et al., 2006) has an increase in glycolytic activity. A significant increase
in lactate levels was observed in 14-16 months old APP/PS-1 mice when compared to
age-matched WT mice. The activity of LDH was also significantly increased in the same
age group.

PDH appears to have an age associated decrease in activity that was

significantly decreased in all age groups when compared to age-matched WT mice.
These findings implicate a possibility of an increased glycolytic activity in APP/PS-1
mice.
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MATERIALS AND METHODS
Determination of Lactate levels
Brains (excluding cerebellum) from six animals from both APP/PS-1 and WT
mice of 3- and 14-16 month old were collected and washed twice in ice-cold PBS, and
homogenized in Dounce homogenizer using Teflon pestle.

The homogenate was

centrifuged at 5000 rpm for 5 minutes and the supernatant was used to determine the
concentration of lactate. The reaction mixture contained 2M Tris; pH 7.5 in water with
0.05% sodium azide, stored at room temperature; 60 mM NAD+ in water, stored at -200C;
15 mM INT, prepared in water containing 10% (v/v) acetone; 100 units/ml Dase in 75
mM Tris; pH 7.5, stored at -200C; and 50 units/ml of lactate dehydrogenase (LDH). Just
prior to the beginning of the assay, Dase was diluted 1:100 with 75 mM Tris, pH 7.5. For
the assay, 50 μl of the reaction reagent was added to 20 μl of the cell lysate in a 96-well
flat bottom microtitre plate. The reaction was allowed to continue for 40 minutes in a
humidified incubator without CO2 at 370C. The reaction was stopped by adding 50 μl of
3% acetic acid, followed by a brief agitation. The absorbance was measured at 492 nm
using a Spectra Max Gemini plate reader from Molecular Devices. The reaction is based
on the production of NADH and pyruvate from NAD and lactate by LDH. This reaction
is coupled to Dase-catalyzed reoxidation of NADH to NAD and reduction of INT to red
colored formazan which is read at 492 nm. The intensity of the red color is proportional
to the concentration of lactate in the sample.
Activity of Lactate Dehydrogenase
Mice

were

euthanized,

brains

(excluding

cerebellum)

were

collected,

homogenized and were used immediately to determine LDH activity, following the
method described by Yen et al. (Yen et al., 1996). Briefly, the homogenized brain was
added to a solution containing NADH and incubated at room temperature for 20 minutes.
Sodium pyruvate (22.7 mM) in 0.1 M potassium phosphate buffer (pH 7.5) was added
after 20 minutes. In the assay, the reaction where pyruvate is converted to lactate
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catalyzed by LDH is followed for two minutes. The decrease in absorbance (dA/min) at
340 nm that occurs with the oxidation of NADH to NAD is used for calculating the LDH
activity using the extinction coefficient of 6.22 mM-1cm-1 for NADH. The activity was
repeated in three independent experiments, each in triplicate.
Activity of Pyruvate Dehydrogenase
The assay is based on the link between the NADH produced by PDH to reduction
of the dye INT and was performed as described by Elnageh & Gaitonde (Elnageh and
Gaitonde, 1988). Briefly, the final reaction mixture of 1 ml volume consisted of 50 mM
Tris-HCL, 0.5 mM EDTA and 0.2% (wt/vol) Triton X-100 (pH 7.8), 100 μg of the brain
homogenate, 2.5 mM NAD, 0.1 mM CoA, 1 mM MgCl2, 0.1 mM oxalate, 1 mg of bovine
serum albumin, 0.6 mM INT, 5-7 units of lipoamide dehydrogenase, 0.2 mM TPP and 5
mM pyruvate. After the addition of 4 mM TPP the contents were kept at 370C for 5
minutes. A stable baseline at 500 nm was obtained for the reaction mixture. The reaction
was started by adding 100 mM pyruvate. The absorbance of the mixture at 500 nm was
recorded at the beginning and again after the reaction had been underway for 5 minutes at
370C. Data was obtained from six animals from each genotype.
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RESULTS
The concentration of lactate in brain homogenate from 14-16 month old APP/PS1 mice was significantly increased (p < 0.01) in comparison with its age matched WT
mice (Figure 4.1). The activity of lactate dehydrogenase, an enzyme that catalyzes the
conversion of pyruvate to lactate, was also significantly increased (p < 0.001) in the brain
homogenate of 14-16 month old APP/PS-1 mice, when compared to its age matched WT
mice (Figure 4.2). These results indicate that glycolytic activity is increased in APP/PS-1
mice.
Pyruvate dehydrogenase (PDH) catalyzes the conversion of pyruvate to AcetylCoA, which then enters the tri-carboxylic cycle. Decreased activity of PDH would lead
to accumulation of pyruvate, which can be converted to lactate by lactate dehydrogenase.
The activity of PDH was significantly decreased even in 3 month old mice of APP/PS-1
genotype when compared to WT mice. This decrease in activity was further exaggerated
at 14-16 months of age in APP/PS-1 mice (Figure 4.3).

95

Lactate levels

Figure 4.1 Increased lactate levels in APP/PS-1 mice.
Brains (excluding cerebellum) were homogenised, centrifuged and the supernatant used for
estimation of lactate.
All measurements were performed from six animals. *, p < 0.05, compared with the agematched WT.
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LDH activity

Figure 4.2 Increased activity of lactate dehydrogenase in APP/PS-1 mice.
Brains (excluding cerebellum) were homogenised, centrifuged and the supernatant used for
estimation of LDH activity
All measurements were performed from six animals. ***, p < 0.001, compared with the
age-matched WT.
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PDH activity

Figure 4.3 Decreased activity of pyruvate dehydrogenase in APP/PS-1 mice.
Brains (excluding cerebellum) were homogenised, centrifuged and the supernatant used for
estimation of PDH activity
All measurements were performed from six animals. **, p < 0.01, compared with the agematched WT.
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DISCUSSION
Numerous in vitro studies on various components of cerebral glucose metabolism
of AD have revealed a reduced activity of different enzymes involved in glucose and
energy metabolism. There is also an impairment of glucose carriers in brain endothelial
cells.

Therefore reduced glucose uptake and/or metabolism in the brain has been

suggested as a reason for neurodegenerative loss of neurons and synaptic connections
(Bigl et al., 2003; Bigl et al., 1999).

The glucose uptake studies using of [18F]

deoxyglucose have demonstrated reduced glucose levels in AD brain. However, these
findings do not address whether the decreased deoxyglucose uptake reflects a limited
metabolic capacity of the brain or a mere reduction in energy demand of a diseased organ
(Bigl et al., 1999).
The increase in lactate levels APP/PS-1 mice at 14-16 months of age suggests an
upregulated glycolytic activity. The increased lactate levels implicate a compensation for
the reduced mitochondrial function found in APP/PS-1 mice (Chapter two)
(Anantharaman et al., 2006). Increase in glycolytic activity in the event of reduction in
mitochondrial function is well documented in many tumors (Pedersen, 2007; Schoonen et
al., 1990; Warburg, 1956; Wu et al., 2007). Our results are consistent with report of
lactate transported from astrocytes by astrocyte-neuron shuttle (ANLSH) (Schurr, 2006)
which under the conditions of mitochondrial respiratory inhibition by nitric oxide exhibit
high lactate levels (Almeida et al., 2001). Being the most numerous nonneuronal cell
type in the central nervous system (Tower and Young, 1973) and also being the first cell
to encounter glucose from blood, the possibility of astrocyte being the source of neuronal
lactate is highly likely. Although SH-SY5Y cells are cancer cells which are dependent
on glucose for energy metabolism, increased lactate levels observed in SH-SY5Y cells
(Chapter three), a predominantly neuronal cells line argues that neurons by themselves
could be a source of increased lactate observed in APP/PS-1 mice.
The increased lactate levels were consistent with increase in LDH activity in
APP/PS-1 mice. This is consistent with the documented findings from the brains of AD
patients (Bigl et al., 1999). Although the specific advantage of increased LDH activity in
the brain is unclear, a suppression of LDH resulted in decreased tumorigenicity in
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malignant cells along with increased mitochondrial respiration (Fantin et al., 2006). LDH
utilizes NADH and produces NAD in the process of catalyzing the conversion of
pyruvate to lactate. NADH being the reducing equivalent for the mitochondrial electron
transport chain, its usage by LDH may lead to depression in mitochondrial respiration
and thereby the energy production. Further, as NAD is regenerated, it fuels glycolysis
and results in increased pyruvate production.
An additional way by which lactate levels can increase is in the presence of
compromised PDH activity. Pyrvuate is converted to acetyl-CoA by PDH. In the event
of decreased PDH activity as observed in APP/PS-1 mice, pyruvate gets accumulated.
The fast kinetics of LDH ensures that pyruvate is converted to lactate (Fantin et al.,
2006). PDH is a critical enzyme for carbohydrate oxidation, present in minimal excess in
the brain, and is closely involved in synaptic plasticity (Sorbi et al., 1983). A decrease in
activity of PDH has been documented in AD (Perry et al., 1977). Acetyl-CoA, the
product of pyruvate oxidation by PDH is necessary for the synthesis of acetyl choline, a
neurotransmitter known to be involved in learning and memory processes. Therefore,
any dysfunction of PDH would lead to decreased acetyl-CoA production and may lead to
the cognitive decline associated with AD.

Copyright © Muthuswamy Anantharman 2008
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CHAPTER FIVE
SUMMARY AND FUTURE STUDIES
As AD brain is under pronounced oxidative stress, and mitochondria is the major
source of superoxide radicals, a dysfunction of MnSOD may exacerbate the progression
of the disease. The studies presented in this work were carried out with the goal of
adding more knowledge on the status of nitration and thereby the activity of MnSOD in
AD brain. The data presented in this dissertation strongly suggest that inactivation of
MnSOD contributes to mitochondrial dysfunction and subsequent enhancement of
glycolytic activity. Although it is well recognized that impaired mitochondrial function
can be compensated by an upregulation of glycolysis, to my knowledge, the data
presented here is the first report on the essential role of an anti-oxidant enzyme
influencing this process. This is supported by the data obtained when addressing the
hypotheses, 1) MnSOD is nitrated and inactivated in association with Aβ deposition. 2)
Nitrative inactivation of MnSOD plays an important role in the impairment of
mitochondrial respiratory function resulting in alteration of energy metabolism. 3) The
impairment of mitochondrial respiration observed in APP/PS-1 mice was also associated
with an increase in glycolytic activity.
Nitrative inactivation of MnSOD in the presence of accelerated deposition of Aβ
was studied using homozygous knock-in APPNLh/NLh x PS-1P264L/P264L mouse.
MnSOD was nitrated with an associated reduction in the activity as Aβ deposition
increased in the brains of these mice. Nitration and inactivation of MnSOD showed a
strong correlation with age. Aβ deposition was detectable at the age of 6 months and by
14 months deposition was prominent and widespread encompassing neocortex and
hippocampus. The finding of increased nitration of MnSOD in an age dependent manner
suggested that Aβ deposition may be a cause for MnSOD nitration. This is supported by
the findings of increased nitrotyrosine immunoreactivity in cultured cells treated with βamyloid and in rats subjected to intracerebroventricular infusion of β-amyloid (Mattson et
al., 1997; Tran et al., 2003). Further, studies showing that Aβ induced accumulation of
mitochondrial peroxynitrite (Keller et al., 1998; Mattson et al., 1997), argues for the
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possibility that Aβ deposition with age is the cause of MnSOD nitration in APP/PS-1
mice. Although the presence of MnSOD nitration by 3 months in APP/PS-1 mice in the
absence of any observable Aβ deposits argues against the notion of Aβ induced nitration,
more recently, report on increase in levels of protein nitration in inferior parietal lobule
(IPL) and hippocampus of mild cognitive impairment (MCI) patients implicate a
prominent role for protein nitration during the early events of AD (Butterfield et al.,
2007).
Inactivation of MnSOD in association with nitration is consistent with previous
studies on peroxynitrite mediated nitration of critical tyrosine residues of MnSOD
leading to its inactivation (MacMillan-Crow et al., 1998; Yamakura et al., 1998). In
addition, our data from SH-SY5Y cells showing increased nitration of MnSOD upon
peroxynitrite treatment suggests that in APP/PS-1 mice, nitrative inactivation of MnSOD
might have occurred by Aβ deposition induced peroxynitrite production. APP/PS-1 mice
exhibited a decrease in mitochondrial respiration mediated through complex I, as
measured by oxygen consumption of isolated mitochondria. The reduction was
significant at 9 and 12 months of age when compared to age-matched WT mice. As
APP/PS-1 mice had reduced MnSOD activity, prior to the observed reduction in
respiration, it is possible that reduction of MnSOD activity may be a cause for the
observed reduction in respiration. This is supported by previous data from our lab
demonstrating that MnSOD selectively protects state 3 respiration activity through
complex I substrates and prevented complex I inactivation (Yen et al., 1999). Further,
Kokoszka et al., (Kokoszka et al., 2001) demonstrated in sod 2 +/-, a impaired
mitochondrial respiration adding credence to the possible role of reduced activity of
MnSOD in APP/PS-1 in decreasing the mitochondrial respiration. The data that we
obtained from SH-SY5Y cells, treated with peroxynitrite, demonstrating reduced
complex I activity and mitochondrial function, which was ameliorated by SOD mimetic
and reproduced by MnSOD siRNA strongly suggest a predominant role for MnSOD in
altering respiration. Although there are multiple targets for peroxynitrite in mitochondria
(Cassina and Radi, 1996; MacMillan-Crow et al., 1998; Rusak et al., 2006; Yamakura et
al., 1998), our result demonstrates that MnSOD is an early target in the process of
peroxynitrite-induced mitochondrial dysfunction. MnSOD was inactivated at 1 μM
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peroxynitrite, but respiration was inhibited at 10- fold higher concentrations. Given the
transient nature of peroxynitrite in biological systems, the early inactivation of MnSOD,
an important anti-oxidant enzyme in the mitochondria, is of immense importance.
MnSOD can inhibit peroxynitrite formation in the mitochondria (Radi et al., 1994), but
its inactivation can possibly lead to an increase in intramitochondrial superoxide levels
and additional generation of peroxynitrite (MacMillan-Crow et al., 1996). This can
propagate the initial damaging event that leads to mitochondrial dysfunction (Radi et al.,
1994).

Our results suggested that MnSOD is inactivated followed by respiratory

impairment. However, the efficient functioning of the mitochondrial respiratory chain
depends on the supply of reducing equivalents (NADH & FADH2) chiefly from
tricaboxylic cycle. Any dysfunction of the enzymes involved in Kreb’s cyle would be
expected to result in decreased production of reducing equivalents and an impaired
mitochondrial respiration. Peroxynitrite being a potent oxidant might also affect the
enzymes of Kreb’s cycle.

Effect of peroxynitrite on the activity of isocitrate

dehydogenase, alpha-ketoglutarate dehydrogenase, malate dehydrogenase and succinate
dehyrogenase involved in production of NADH and FADH2 needs to be investigated.
A compensatory upregulation of glycolytic activity has been observed in the event
of decreased mitochondrial function. In APP/PS-1 mice, we observed increased levels of
lactate, an index of increased glycolysis. This, when taken together with the data of
reduced activity of MnSOD, decreased mitochondrial respiration in APP/PS-1 mice and
the finding of MnSOD in maintaining the mitochondrial function suggest that MnSOD is
influencing the metabolic switch to glycolysis in APP/PS-1 mice.

This notion is

supported by the data from SH-SY5Y cells which showed increased levels of lactate on
peroxynitrite treatment, preventable by SOD mimetic and reproduced by MnSOD siRNA.
Severe impairment of the ability to oxidize substrates through pyruvate dehydrogenase
(PDH), tricarboxylic acid cycle or electron transport chain are likely to lead to
accumulation of lactate. In this study, we encountered a decreased activity of PDH and
impaired mitochondrial function in APP/PS-1 mice and also in SH-SY5Y cells treated
with peroxynitrite. These might have resulted in increased lactate levels, without an
actual increase in glycolytic activity. Lactate also arises from amino acid alanine, which
is converted to pyruvate by alanine amino transferease. But, in our system there is
103

reduced activity of PDH. Hence, pyruvate cannot enter the TCA cycle and is instead
converted to lactate. Acetyl CoA formed from beta oxidation of fatty acids can also
contribute to increased lactate levels by inhibiting PDH. This inhibition would lead
accumulation of pyruvate that is converted to lactate. In this dissertation work, we have
not addressed the contribution from these respective sources. Therefore, to add credence
to our finding of increased glycolysis, the contribution to lactate levels by amino acids
and fatty acids should be quantified. Further, by redox proteomics approach, enzymes
like enolase and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) are shown to be
nitrated in the brains of AD patients. If this is true, we should have encountered a
decrease in glycolytic activity, which we did not. Perhaps, the treatment regimen that
was followed in this dissertation (24 hours treatment of SH-SY5Y cells with
peroxynitrite) was not sufficient to cause nitration of glycolytic enzymes or probably
glycolytic enzymes are in abundance, to keep the glycolysis active, even in the presence
of nitrated and possibly inactivated proteins.
As mitochondrial function is a prerequisite for the majority of ATP produced in a
cell, any dysfunction would be expected to result in a decreased ATP levels.

A

compensatory increase in glycolytic activity may offset ATP loss, which was the case, as
we observed comparable ATP levels in control and peroxynitrite treated SH-SY5Y cells.
As in many tumors, where an increase in glycolytic activity is supported by enhanced
glucose uptake into the cells, peroxynitrite treated SH-SY5Y cells showed significantly
increased concentrations of glucose when compared to untreated cells. Further, our
observation of decreased respiration, decreased complex I activity and increased lactate
in the MnSOD heterozygous knock-out mice adds credence to the hypothesis that
decreased activity of MnSOD is contributing to a switch from oxidative phosphorylation
to glycolysis in AD.
The finding of enhanced glycolysis in our AD mouse model is in contrast to that
of human AD patients, where an impaired glucose metabolism has been reported. The
following reasons could explain the apparent inconsistency between these studies,
1. The human data is based on glucose uptake studies using PET imaging. This does
not clearly indicate whether there is a true limited metabolic capacity of the brain
or a mere reduction in energy demand of a diseased organ (Bigl et al., 1999).
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1. Further, the neuronal loss encountered in AD may also account for reduced
glucose uptake or probably the loss of neurons is so abundant that a compensatory
enhancement of glycolytic activity in the remaining neurons may not be sufficient
to manifest as an increase.
2. The age group of APP/PS-1 mice (14 - 16 months) used to analyze the lactate
levels may not be comparable to aged human AD patients. The increase in
glycolytic activity is perhaps occurring at a very early age in humans, which if
found might be utilized as a potential target for modulating the progression of
AD.
3. APP/PS-1 mice have not been shown to develop neurofibrillary tangles, which
may be necessary to reproduce the metabolic changes occurring in humans.
To further elucidate the role of MnSOD in altering the mitochondrial function and
glycolytic activity, it would be worthwhile to investigate in vivo by injecting SOD
mimetic in APP/PS-1 mice. Primary neurons from APP/PS-1 mice exhibit increased
colocalization of nitrotyrosine with MnSOD, decreased mitochondrial function and
increased susceptibility to Aβ treatment (Sompol et al., 2008). So it would be interesting
to investigate whether these primary neurons have increased glycolytic activity. Further,
APP/PS-1 mice do not develop neurofibrillary tangles and show neuronal loss, it does not
recapitulate the complete AD pathology encountered in human beings. Therefore, to
make the findings of this study more relevant to human AD, a triple transgenic mouse
exhibiting all the pathological hallmarks of human AD could be utilized to study the
effect of MnSOD on glycolysis.

Copyright © Muthuswamy Anantharman 2008
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Figure 5.1 Hypothetical model suggested from the data obtained.
Nitric oxide produced by surrounding microglia or astrocytes or by the neurons itself,
diffuse into the mitochondria and inhibit complex IV. Inhibition of complex IV lead to
electron leak and superoxide production. Superoxide can react with nitric oxide to result in
peroxynitrite formation. MnSOD is nitrated and inactivated at low concentrations of
peroxynitrite produced leading to accumulation of superoxide and peroxynitrite.
Increasing concentrations of these can inhibit respiratory chain and thereby the
mitochondrial respiration. Inhibition of mitochondrial respiration leads to increase in
glycolytic activity to offset any ATP loss. Black dashed lines and words in black – known
in the literature; red arrows and words in red – data obtained from this dissertation; yellow
box with words in black – indicated in the existing literature but not proven.
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